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Abstract: 
 
CRISPR (clustered regularly interspaced short palindromic repeat) systems have been broadly 
adopted for basic science, biotechnology, and gene and cell therapy. In some cases, these 
bacterial nucleases have demonstrated off-target activity. This creates a potential hazard for 
therapeutic applications and could confound results in biological research. Therefore, improving 
the precision of these nucleases is of broad interest. Here we show that engineering a hairpin 
secondary structure onto the spacer region of single guide RNAs (hp-sgRNAs) can increase 
specificity by several orders of magnitude when combined with various CRISPR effectors. We 
first demonstrate that designed hp-sgRNAs can tune the activity of a transactivator based on 
Cas9 from Streptococcus pyogenes (SpCas9). We then show that hp-sgRNAs increase the 
specificity of gene editing using five different Cas9 or Cas12a variants. Our results demonstrate 
that RNA secondary structure is a fundamental parameter that can tune the activity of diverse 
CRISPR systems. 
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Article: 
 
CRISPR–Cas systems are adaptive immune systems in bacteria and archaea, and have proven to 
be robust genome editing platforms1. Efforts to repurpose CRISPR–Cas systems for genome 
editing have largely focused on class 2 CRISPR systems because of their simplicity. While class 
1 systems use multi-protein complexes to target nucleic acids, class 2 systems use a single Cas 
protein, termed the Cas effector, which can be easily reconstituted and harnessed for a variety of 
applications2. 
 
The arms race between viruses and prokaryotes has driven immense genetic diversity of Cas 
effectors. Each Cas effector has unique properties (for example, nucleic acid preference, 
protospacer-adjacent motif (PAM) requirements, size of the Cas effector) that endow it with 
advantages and disadvantages for particular applications. The identification and characterization 
of class 2 CRISPR systems is thus an active area of research, with the overarching goal of 
finding Cas effectors with novel or improved properties3,4,5. Since the initial characterization of 
SpCas9, the number of Cas effectors active in mammalian cells has expanded to include compact 
Cas9 effectors from the type II CRISPR systems, Cas12a (previously Cpf1) effectors with 
(A+T)-rich PAMs from type V systems and RNA-targeting Cas13 variants6,7,8,9,10,11,12. 
 
Although these nucleases are versatile tools for gene editing outside of their native environments, 
they also have off-target effects, leading to unintended DNA breaks at sites with imperfect 
complementarity to the spacer sequence13,14,15. Thus, improving the specificity of these nucleases 
is a critical goal, especially for gene therapy applications16. Methods to increase the specificity of 
class 2 CRISPR systems through rational design have largely focused on SpCas9 and have 
adopted two general strategies. The first strategy is to create an AND gate that requires 
coordinate binding of two Cas9 molecules, imposing a stricter requirement for nuclease 
activity17,18,19,20. The second strategy is to reduce the energetics of DNA interrogation by the 
Cas9–single guide RNA (sgRNA) complex, which results in an overall increase in 
specificity21,22,23,24,25. The second strategy is particularly attractive because, unlike the first 
strategy, it does not increase the number of components of the gene editing system. This 
simplifies gene delivery, which is often a critical barrier. While previous efforts with either 
strategy were successful, they suffer from one or more of a variety of limitations, including 
incompatibility with viral packaging constraints, a greater number of components of the system 
and the requirement for extensive protein engineering. Recent studies that employ directed 
evolution rather than rational design have yielded many new variants with improved 
properties26,27,28. However, it remains to be seen which of these many approaches will have 
general applicability across CRISPR systems. Thus, there is a need for a simple method for 
increasing specificity of diverse CRISPR systems. 
 
Employing rational design and adopting the second strategy, we hypothesized that engineering 
the sgRNA might serve as a means to regulate diverse CRISPR systems. Specifically, we 
engineered RNA secondary structure onto the spacer by extending a designed hairpin on the 5′ 
end of the sgRNA (hp-sgRNA). The resulting hairpin structure could then serve as a steric and 
energetic barrier to R-loop formation. We hypothesized that by adjusting the strength of the 
secondary structure, R-loop formation could proceed to completion at the on-target site but could 
be impeded at off-target sites, which have reduced energetics due to RNA–DNA mispairing. 
Because R-loop formation is the critical process governing the conformational change of SpCas9 
to an active nuclease29,30, this would block off-target nuclease activity and result in an increase in 
specificity. Since CRISPR endonucleases accommodate a nucleic acid duplex within their 
binding channel, we hypothesized that the RNA–RNA duplexes of hp-sgRNAs could also be 
accommodated without interfering with formation of the sgRNA–protein complex. Moreover, 
hp-sgRNAs are simple to design and produce: RNA hairpins generally follow Watson–Crick 
base-pairing guidelines, and sgRNA production methods are rapid and inexpensive. 
 
Results 
 
Design considerations for hp-sgRNAs 
 
RNA can fold into many different complex structures. For our initial engineered structures we 
adopted the RNA hairpin, a fundamental structural unit in many RNA molecules31. RNA 
hairpins are composed of two components, stems and loops, which we create by extending the 
PAM-distal end of the spacer to generate hp-sgRNAs (Fig. 1a). All designs were informed 
through the use of in silico structure determination, and only spacer sequences were used for 
these predictions (that is, structural sequences in the tracrRNA or crRNAs were excluded). 
 
Figure 1. Engineered RNA secondary structures tune the activity of dCas9-P300. a, 
Structure of the WT-sgRNA for SpCas9 and design parameters of hp-sgRNAs. b, Gene 
activation of IL1RN using hp-sgRNAs with varying stem lengths, measured by qRT–PCR. 
Hairpin sgRNAs are abbreviated as ‘hp’, non-structured controls are abbreviated as ‘ns’ and 
numbers indicate the number of nucleotides added 5′ of the spacer. Data are shown as fold 
increase relative to the control sample, which was transfected with dCas9-P300 only. Error bars 
represent s.e.m. for n = 3. All hp-sgRNA variants show significant activation over 
control, P < 0.005 using a two-sided t-test after a global one-way analysis of variance 
(ANOVA). c, Replotting the mean of each group in b as a function of the predicted folding 
energy of each hp-sgRNA’s engineered secondary structure. Trends in the data are annotated for 
clarity (for example, ‘Region 1’). The sequences of all sgRNAs used are listed in Supplementary 
Table 1. 
 
We expected thermodynamic stability of the secondary structure to be an influential 
characteristic of hp-sgRNAs. However, there are many variables one can use to create different 
structures with similar stability (Fig. 1a). The stem can be placed along any area of the 20-
nucleotide spacer, which may have variable effects on R-loop formation kinetics. Stem lengths, 
the major determinant of hairpin stability, can also be varied. To modulate stability but not 
necessarily overall hp-sgRNA structure, non-canonical rG-rU base pairs can be substituted for 
potential rG-rC/rA-rU sites in the stems. Many RNA hairpins found in nature utilize 5′-ANYA-3′ 
or 5′-UNCG-3′ tetraloops, which have favorable base-stacking behavior32. We utilize these 
tetraloops for our initial structures, but one can also use part of the spacer itself for the hairpin 
loop. In this study, all of these variables were used to generate hp-sgRNAs. Furthermore, to 
control for any effects of sgRNA length, we also designed non-structured sgRNAs (ns-sgRNAs), 
which have extensions to the spacer but whose extensions are not predicted to form any 
secondary structures. 
 
hp-sgRNAs regulate a SpCas9-based transcriptional activator 
 
We first tested the effect of predicted hp-sgRNAs structures on Cas9 binding to DNA. Critically, 
we wanted to analyze this interaction in human cells, where reports have shown that extensions 
to the 5′ end of the sgRNA can be processed back to lengths of the native spacer19,33. We thus 
decided to utilize nuclease-inactive dCas9-based transcriptional activators34,35, where 
endogenous gene activation can serve as a sensitive measure of dCas9 binding to target DNA. 
 
For our initial hp-sgRNA designs, we used a tetraloop that is external to the 20-nucleotide spacer 
and placed the hairpin stems on the PAM-distal end of the spacer using canonical Watson–Crick 
base pairing. We used a spacer that targets the endogenous promoter of IL1RN, a gene we have 
previously activated with high efficiency34,35. Transfecting sgRNA variants and a dCas9-P300 
transactivator into human cells, we observed that hp-sgRNAs can tune gene activation at the 
target locus (Fig. 1b), suggesting modulation of dCas9 binding. 
 
We observed a generally regular relationship between length of the hp-sgRNA spacer extension 
and impact on dCas9 binding (Fig. 1b). The only irregularity was observed with hp15, which has 
an unpaired 5′ guanine, necessitated by the U6 promoter. Replotting the activity of each hp-
sgRNA variant as a function of thermodynamic stability of their predicted structures, we 
observed a monotonic decrease of gene activation over four orders of magnitude (Fig. 1c). These 
data provide evidence that the predicted RNA structures form in human cells and demonstrate 
that the in silico predicted free energy of the structures is an accurate predictor of its regulatory 
effect on dCas9 binding to genomic DNA (gDNA) target sites. 
 
Notably, use of ns-sgRNAs did not decrease transactivation to the same degree as seen with hp-
sgRNAs, indicating that hairpin formation, and not simply sgRNA extension, was responsible for 
modulating dCas9 binding. However, on average, ns-sgRNAs caused a ~2.8-fold reduction in 
gene activation when compared with the unmodified guide (wild-type sgRNA (WT-sgRNA)). 
This is consistent with other evidence of spacer length having subtantial effects on the efficiency 
of dCas9-based transcriptional regulators36, underscoring the need to control for guide length 
when measuring the effects of sgRNA secondary structure. In fact, length effects may be the 
underlying cause for the observation that sgRNAs with guanine-dinucleotide extensions have 
increased specificity37. 
 
These data describe nonlinear effects of 5′ sgRNA extensions on SpCas9 binding to DNA, 
dependent on both the length and secondary structure of the spacer. This relationship is 
characterized by three key regions in the data (Fig. 1c). First, extensions to the 20-nucleotide 
spacer cause a decrease in overall binding that is independent of secondary structure (Fig. 1c, 
‘Region 1’). Second, extensions that form weaker predicted secondary structures do not seem to 
have measurable effects on SpCas9 binding beyond those caused by length effects (Fig. 1c, 
‘Region 2’); however, it is possible that R-loop formation is still being inhibited in this 
region38,39. Finally, more stable hairpins cause measurable decreases in Cas9 binding as a 
function of the strength of the hp-sgRNA’s secondary structure (Fig. 1c, ‘Region 3’). Further, 
these decreases in activity occur as the hairpin extends into the seed region of the sgRNA that is 
critical for initiating the interaction between Cas9 and a target. The trend of hairpin structure 
modulating targeted gene activation was corroborated at two additional gene targets in human 
cells (Supplementary Fig. 1). 
 
Although we ascribe the changes in gene activation to modulation of R-loop formation by hp-
sgRNAs, previous studies showed by northern blot that 5′ extensions to sgRNAs were efficiently 
processed to 20-nucleotide spacers19,33. To control for both processing of the hairpins and 
expression of sgRNA variants, we repeated this experiment, collected total RNA and performed 
sample-matched measurements of IL1RN and sgRNA expression by reverse transcription with 
quantitative PCR (RT–qPCR), and 5′ sgRNA processing by 5′ rapid amplification of cDNA ends 
(RACE) followed by RNA sequencing (Supplementary Fig. 2a,b). Patterns in IL1RN gene 
activation were faithfully replicated (Supplementary Fig. 2c,d). We observed no correlation 
between hp-sgRNA expression and hp-sgRNA activity (Supplementary Fig. 2e,f). 
 
In contrast to the previous reports19,33, we observed that hp-sgRNAs are moderately to minimally 
processed, with stronger predicted secondary structures undergoing less processing 
(Supplementary Fig. 2g, range 0.8–48% processed). The corresponding ns-sgRNAs had higher 
rates of processing (Supplementary Fig. 2h, range 52–79% processed). We observed no clear 
association between the level of hp-sgRNA processing and IL1RN transactivation 
(Supplementary Fig. 2i,j). These data suggest that hp-sgRNAs are maintained in cells and can be 
accommodated within the Cas9 binding pocket where they are protected from processing. 
 
Kinetic modeling of R-loop formation 
 
The differences in behavior between hp-sgRNAs and ns-sgRNAs indicate that the secondary 
structure of the spacer is a critical determinant of CRISPR activity. To gain a better 
understanding of how spacer secondary structure might affect SpCas9 behavior, we applied a 
kinetic model of R-loop formation and generalized it to accommodate any species of 
mismatches, an arbitrary number of mismatches and RNA secondary structure (Fig. 2a)29. Strand 
invasion is represented as a series of 20 discrete states and the probability of exchange between 
states is governed by 3 energetic processes: (1) hybridization or melting of the genomic target 
(DNA-DNA), (2) the hybridization or melting of the spacer to the genomic target (RNA–DNA) 
and (3) the breaking or forming of spacer secondary structure (RNA–RNA). This approach 
defines the kinetics of R-loop formation entirely in terms of empirically measured 
thermodynamic values of nucleic acid pairs (see Methods). 
 
To test the model, we used previously reported chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) data of 16 sgRNAs and 12,181 called binding sites of dCas940,41. We 
simulated the mean residence time of each of the 16 sgRNAs to each of the reported binding 
sites, compared this simulation with the measured ChIP-seq signal and combined correlations 
across sgRNAs using Fisher’s method. We find correlation coefficients of 0.285 (95% 
confidence: 0.252, 0.317) when the simulation is initiated at the PAM-proximal site and a 
correlation of 0.380 (95% confidence: 0.349, 0.410) if initiated with a preformed R-loop 
(Fig. 2b). These correlations were higher than the previously reported best performing feature, 
chromatin accessibility40. The predictive power of our model demonstrates that the dynamics of 
R-loop formation play an important role in Cas9 binding to DNA. 
 
Figure 2. Spacer secondary structure improves the performance of a kinetic model of R-
loop formation. a, Schema of kinetic model of R-loop formation. Left panel: modeled molecular 
interactions. The target DNA is shown in green and sgRNA spacer is shown in red with both a 
mismatch and RNA secondary structure. Center panel: distinct states representing degree of R-
loop formation by the spacer. The forward and reverse rates between states are calculated using 
the free energy differences between states (see Methods). Right panel: Q-matrix of forward and 
reverse reaction rates. The starting state of the simulation is represented by vector α0. b, 
Correlation between model-based predictions of binding lifetime and the ChIP-seq intensity40,41. 
Model was initiated with a preformed R-loop. For each sgRNA, log(L) was correlated (Pearson) 
with log(ChIP-seq intensity), and these correlations combined using Fisher’s method, n = 12,181. 
c, Correlation coefficients with (ρ = 1) and without (ρ = 0) energetic contributions from spacer 
secondary structure, for various starting states. Plots show the calculated Pearson correlation 
coefficient, and error bars are 95% confidence intervals. d, Simulated values of the mean binding 
lifetimes for sgRNA variants, shown in Fig. 1b, plotted against their activation of 
the IL1RN gene, n = 12. 
 
To determine the contribution of spacer secondary structure to the model’s predictive power, we 
removed the energetic terms for RNA folding from the reaction rates. We observed a decrease in 
correlation from 0.285 to 0.194 (95% confidence: 0.160, 0.228) if the simulation is initiated at 
the PAM-proximal nucleotides or from 0.380 to 0.273 (95% confidence: 0.240, 0.305) if the 
simulation is initiated with the R-loop already preformed (Fig. 2c). Finally, we performed 
simulations to predict the behavior of the hp-sgRNA variants used to modulate the expression of 
the IL1RN promoter in Fig. 1 (Fig. 2d). We found a strong correlation, 0.915, between estimated 
binding lifetime and fold increase in gene expression. Collectively, these findings suggest that 
spacer secondary structure influences Cas9 binding activity by modulating invasion kinetics and 
stability of the R-loop, key determinants of nucleolytic activation of SpCas930. 
 
hp-sgRNAs increase the gene editing specificity of SpCas9 
 
We next assessed the effect of spacer secondary structure on SpCas9 nuclease activity. It was our 
hypothesis that hairpin structures could increase nuclease specificity by modulating R-loop 
formation without necessarily altering binding to target sites29,30. Thus, for hp-sgRNAs designed 
for the SpCas9 nuclease, we generally chose hairpins with predicted free energies weaker than 
−15 kcal mol−1, that is, within Region 1 of Fig. 1c, since any further increase in hairpin stability 
resulted in significant decreases in SpCas9 binding to its on-target site. To assess the effects of 
engineered hp-sgRNAs on the nuclease activity and specificity of Cas9 in human cells, we chose 
spacers that have large numbers of well-characterized off-target sites42. We generated a variety 
of hp-sgRNAs for these spacers where we varied several hp-sgRNA structural characteristics, 
including utilizing both external and internal loops or adjusting PAM-distal and PAM-proximal 
stem placement. We measured indel frequency at on-target and off-target sites for each spacer 
and compared the activity of these hp-sgRNAs to activities of both unextended sgRNAs (WT-
sgRNAs) and truncated sgRNAs (tru-sgRNAs)23. We observed a number of hp-sgRNA designs 
with on-target activities comparable to WT-sgRNAs and reduced off-target activity, comparable 
to tru-sgRNAs (Fig. 3a–c and Supplementary Figs. 3–7). We defined a specificity metric by 
dividing on-target mutation rates by the sum of all off-target mutation rates. All optimized hp-
sgRNAs significantly increased the specificity of SpCas9, on par with increases observed with 
tru-sgRNAs (Fig. 3d and Supplementary Fig. 6e). hp-sgRNA 7 of the EMX1.1 spacer, which had 
the highest fold increase in specificity, had both a spacer truncation and designed secondary 
structure, suggesting that these approaches may be combined in some cases (Supplementary 
Fig. 6e). We observed that tru-sgRNAs increase off-target activity at 8 of the 37 off-target loci 
(Fig. 3a–c). This increase may be due to the decreased sequence complexity of tru-sgRNAs and 
was not observed for any hp-sgRNA variants, consistent with hp-sgRNAs behaving in an entirely 
inhibitory manner (Fig. 3a–c and Supplementary Fig. 6a–c). Collectively these results show that 
hp-sgRNAs can increase the specificity of SpCas9 nuclease by multiple orders of magnitude. 
 
To test whether the 5′ extensions of hp-sgRNAs might lead to any new off-target cleavage events 
beyond what had previously been identified for the corresponding WT-sgRNAs, we performed 
CIRCLE-seq (circularization for in vitro reporting of cleavage effects by sequencing), an 
unbiased in vitro method to determine genome-wide cleavage events43. We performed CIRCLE-
seq using the EMX1.1 spacer and used WT-, tru- and, hp-sgRNA variants; off-targets were 
reliably identified across replicates for each sgRNA variant (Supplementary Fig. 7a–d). 
Comparing with WT-sgRNA, the tru-sgRNA eliminated 77 off-target sites but also had 25 
unique off-target sites that were reproducibly detected using CIRCLE-seq (Supplementary 
Figs. 8a and 9a, b). In contrast, the hp-sgRNA eliminated 124 off-target sites found with the WT-
sgRNA and generated no unique off-target sites (Supplementary Figs. 8b and 9a, c). 
 
Figure 3. hp-sgRNAs increase the specificity of SpCas9 in human cells. a–c, On-target and 
off-target mutation rates for sgRNA variants targeting the EMX1 and VEGFA genes, measured 
by deep sequencing: VEGFA spacer 1 (a), EMX1 spacer 1 (b) and VEGFA spacer 2 (c). ‘Percent 
modified’ indicates percentage of reads containing indels compared with the wild-type sequence 
(mean + s.e.m., n = 3). WT-sgRNAs (‘WT’) generated significant editing activity at all off-target 
sites, except for VEGFA spacer 2 at OT10 (P < 0.01). hp-sgRNAs show significant decreases in 
activity at all measured off-target sites when compared with WT-sgRNA (P < 0.05). Hypothesis 
testing using a one-sided Fisher exact test with pooled read counts, adjusting for multiple 
comparisons using the Benjamini–Hochberg method. d,e, On-target activity (d) and specificity 
metric (e) for different sgRNA variants. Samples labeled as ‘hairpin’ use the same hairpin 
variant listed in panels a–c. The specificity metric is defined as on-target indel rate divided by 
the sum of all off-target indel rates (mean + s.e.m., n = 3). The sequences of sgRNA variants are 
listed in Supplementary Table 1. The predicted structures of hp-sgRNAs are displayed in 
Supplementary Figs. 3–5. 
 
Fig. 4: hp-sgRNAs retain binding activity at off-target loci. a, dCas9 enrichment at the on-
target site using sgRNA variants containing EMX1 spacer 1 by ChIP-qPCR. The WT-sgRNA 
sample had significant enrichment over control, P < 0.001. The tru-sgRNA and hp-sgRNAs 
showed a decreased enrichment relative to WT-sgRNA, P < 0.05. b–d, dCas9 enrichment at 
designated off-target sites (OT1 (b), OT2 (c), OT3 (d)) using sgRNA variants containing EMX1 
spacer 1 by ChIP-qPCR. hp-sgRNAs were also assayed for editing activity with nuclease-active 
SpCas9 (Supplementary Fig. 6b), and their predicted secondary structure is shown in 
Supplementary Fig. 1. e, Off-target editing rates, as shown in Supplementary Fig. 5b, as a 
function of corresponding DNA binding as measured by ChIP-qPCR. Hairpin 2, when compared 
with WT, showed significantly decreased editing activity at off-target sites (P < 5 × 10−20), but 
showed no significant decreases in ChIP enrichment (mean + s.e.m., n = 3). P values for ChIP-
qPCR data were calculated using a post hoc Tukey test after a global one-way ANOVA. For 
editing activity, hypothesis testing was carried out using a one-sided Fisher exact test with 
pooled read counts, adjusting for multiple comparisons using the Benjamini–Hochberg method. 
All fold enrichments are relative to transfection of a control sgRNA plasmid targeted to 
the IL1RN promoter and normalized to a region of the β-actin locus. The sequences of sgRNA 
variants are listed in Supplementary Table 1. 
 
We next sought insight into the mechanism of specificity increases driven by hp-sgRNAs—in 
particular, whether this was a result of decreased binding to DNA. We performed chromatin 
immunoprecipitation with quantitative PCR (ChIP-qPCR) to measure the relative enrichment of 
the nuclease-null dSpCas9 at on-target versus off-target sites using the same EMX1 spacer tested 
with nuclease-active SpCas9. We observed that both the hp-sgRNAs and tru-sgRNA yielded 
similar levels of dCas9 occupancy at the on-target site (Fig. 4a). Interestingly, hp-sgRNA 2 did 
not measurably decrease dCas9 occupancy at any of the measured off-target sites relative to the 
WT-sgRNA (Fig. 4b–d), even though nuclease activity was reduced at these sites by an order of 
magnitude or more (Fig. 4e and Supplementary Fig. 6b). This suggests that, similar to high-
fidelity Cas9 variants24, hp-sgRNAs do not mediate specificity increases through a decrease in 
binding. Hp-sgRNA 7 had more variable behavior, which we attribute to the combination of a 
hairpin and a truncated spacer. 
 
hp-sgRNAs increase specificity of Cas9 and Cas12a variants 
 
We next tested whether hp-sgRNA designs can be extended to other CRISPR systems. In 
particular, we were interested in SaCas9 because its compact size facilitates delivery by AAV 
vectors and is therefore of significant interest for gene therapy applications6,44. While SaCas9 
and SpCas9 have many analogous domains and a similar bilobed structure, they share only 17% 
sequence similarity45. 
 
Focusing on SaCas9 and SaCas9-KKH, a relaxed PAM variant, we designed hp-sgRNAs of 
varying stem lengths using target sites with previously characterized off-target effects6,13. We 
delivered sgRNA variants with each SaCas9 to human cells and assayed for nuclease activity at 
on-target and off-target loci. Similar to SpCas9, SaCas9 activity is tuned by hp-sgRNAs 
according to the strength of predicted secondary structure (Fig. 5a,b and Supplementary 
Fig. 10a–c). tru-sgRNAs of varying length were also used, though they did not eliminate off-
target activity without severely impacting on-target activity; shorter truncations resulted in 
complete abrogation of off-target and on-target nuclease activity (Fig. 5a,b and Supplementary 
Fig. 10a–c; data not shown). 
 
We next tested whether hp-sgRNAs could be applied to type V Cas12a nucleases. While SpCas9 
and Cas12a share a bilobed architecture, they share no structural or sequence homology other 
than a single RuvC domain46. Cas12a nucleases are unique in that they can process their own 
crRNAs, and these crRNAs are sufficient for Cas12a target recognition and cleavage47. Cas12a 
recognizes its crRNA via a hairpin that is at the 5′ end of the crRNA and the spacer is at the 3′ 
end: the reverse orientation relative to Cas9 sgRNA structure. Target recognition by Cas12a and 
R-loop formation mechanisms are also reversed when comparing with that of Cas9: the PAM 
sequence is located at the 5′ end of the target sequence and R-loop formation of the target strand 
proceeds 3′ to 5′. Despite these many differences, we hypothesized that the activity of Cas12a 
nucleases could also be regulated by spacer secondary structure. Using a spacer with previously 
characterized off-target sites14,15,48, we designed hp-crRNAs with varying structural stability. We 
observed that both AsCas12a and LbCas12a activity can be regulated by spacer secondary 
structure and that off-target activity can be reduced without altering on-target activity by tuning 
the strength of the secondary structure (Fig. 5c,d and Supplementary Fig. 11a–c). Truncated 
crRNAs did not consistently result in specificity increases for either AsCas12a or LbCas12a, 
indicating that this strategy might not be consistently translatable to Cas12a nucleases (Fig. 5c–
d and Supplementary Fig. 11a–c). Shorter truncations of the spacer resulted in complete 
abrogation of off-target and on-target nuclease activity. We observed that hp-crRNAs influence 
the activity of Cas12a nucleases according to the strength of the secondary structure, consistent 
with the effect of hp-sgRNAs on SpCas9 and SaCas9 activity (Fig. 5c,d and Supplementary 
Fig. 11a–c). Significantly, as predicted folding energy increases, decreases in gene editing 
activity occur preferentially at off-target loci, allowing for increases in specificity (Fig. 5i). 
 
 
Figure 5. hp-sgRNAs and -crRNAs increase the specificity of various Cas effectors. a–d, 
On-target and off-target nuclease activity of sgRNA and crRNA variants with SaCas9 (a), 
SaCas9-KKH (b), LbCas12a (c) and AsCas12a (d). Plasmids encoding the Cas effector and the 
sgRNA or crRNA variant were transfected into human cells and mutational activity was 
measured using the Surveyor nuclease assay. Representative gels are shown from optimizations 
that were performed one to three times. Optimized structures were further investigated with deep 
sequencing in Fig. 6. Aliases for sgRNA variants are listed above each lane and are detailed in 
Supplementary Table 1. tru-sgRNAs/crRNAs are abbreviated as ‘Tru’, hp-sgRNAs/crRNAs are 
abbreviated as ‘Hp’ and non-structured controls are abbreviated as ‘N.s.’. For LbCas12a, off-
target activity was generated by introducing a mismatch in the sgRNA spacer, as shown, and is 
referred to as a ‘pseudo-off-target’. e–h, Predicted structure of optimized hp-sgRNA spacers 
(hairpin 1 (e), hairpin 3 (f), hairpin 1 (g), hairpin 4 (h)); arrows indicate 3′ end of RNA. The 
sequences of the sgRNA variants are listed in Supplementary Table 1. i, Normalized nuclease 
activity of WT-sgRNAs and various hp-sgRNAs, plotted against their predicted free energy of 
secondary structure folding. Data from panels a–d were normalized to the WT-sgRNA activity at 
the corresponding on-target (solid line) or off-target site (dotted line). 
Figure 6. RNA secondary structure drives the specificity increases observed with hp-
sgRNAs. a–e, Nuclease activity of hp-sgRNAs/crRNAs and corresponding non-structured 
controls in human cells, applied with SaCas9, SaCas9-KKH, AsCas12a, AsCas12a-RVR and 
LbCas12a, respectively. Deep sequencing was used to measure editing activity of Cas effector-
sgRNA pairs. WT-sgRNAs induced significant editing activity at all off-target sites 
(P < 1 × 10−9). hp-sgRNAs/crRNAs significantly reduced editing activity at all examined off-
target sites when compared with WT-sgRNA/crRNA (P < 5 × 10−11). Hypothesis testing was 
carried out using a one-sided Fisher exact test with pooled read counts, adjusting for multiple 
comparisons using the Benjamini–Hochberg method. f, Specificity metric for sgRNA variants 
applied with the indicated Cas effector (mean + s.e.m., n = 3). The gene target of each spacer is 
listed on the x axis. 
 
To confirm that increases in specificity are caused by RNA secondary structures, we generated 
ns-sgRNAs for hp-sgRNAs used with Cas9 and Cas12a effectors. For each Cas effector we 
generally chose hp-sgRNA variants that maintained on-target activity but had the most stable 
predicted free energy. We delivered these sgRNA variants with their respective Cas nuclease and 
used deep sequencing to assay mutational rates at both on-target and off-target loci (Fig. 6a–e). 
Across 12 spacer sequences and 6 different Cas9 or Cas12a variants, hp-sgRNAs increased 
specificity by an average of 55-fold (median 12-fold) compared with unmodified sgRNAs and 9-
fold compared with length-matched non-structured control sgRNAs (Fig. 6f and Supplementary 
Fig. 12). Hp-sgRNAs showed particular sensitivity to off-targets with multiple mismatches 
(Supplementary Fig. 13). 
 
To further ensure that the specificity increases were due to modulation of kinetics of R-loop 
formation, rather than changes to expression or stability that could occur within transfected cells, 
we completed in vitro assays for nuclease activity and DNA binding. For in vitro nuclease 
activity, we digested PCR amplicons containing the on-target EMX1 spacer 1, EMX1 spacer 2 
or DNMT1 spacer 1, by defined concentrations of purified SpCas9, SaCas9 or AsCas12a protein, 
respectively, complexed with corresponding chemically synthesized WT-, hp- or ns-sgRNAs 
(Supplementary Fig. 14). At the on-target sites, the activity of the hp-sgRNAs was reduced by 
85%, 59% and 69% relative to activity of WT-gRNAs at the on-target sites for SpCas9, SaCas9 
and AsCas12a, respectively, compared with a reduction of 12% and increases of 35% and 6% 
with the corresponding ns-sgRNAs. The significant reduction of activity of hp-sgRNAs at on-
target sites in vitro, but not in cells (Figs. 3b,d and 6a,c), may be the result of the short time 
frame of the assay or other differences with the intracellular environment in which these 
particular hairpin structures were optimized. We also tested identical digestion reactions with 
PCR amplicons containing the corresponding off-target 1 (OT1) spacer sequence. At the off-
target sites, hp-sgRNAs also showed decreases of 91%, 79% and 67% relative to WT-sgRNAs, 
compared with decreases of 88%, 38% and 0% for the ns-sgRNAs. To assay DNA binding, we 
used atomic force microscopy (AFM) to directly image and quantify interactions of the same 
combinations of Cas effectors and sgRNAs at on-target and off-target sequences (Supplementary 
Fig. 15). These analyses showed that only hp-sgRNAs, and not ns-sgRNAs, robustly and 
reproducibly decreased occupancy at off-target sites relative to the on-target site. Collectively, 
these data support that, under controlled conditions of in vitro reactions, hairpin structure—and 
not simply any 5′ extension—modulates CRISPR activity. 
 
Discussion 
 
CRISPR–Cas endonucleases did not evolve to function for highly specific gene editing of 
mammalian genomes, and cases of off-target activity have been reported for the majority of 
CRISPR endonucleases tested so far in human cells. Additionally, the discovery of novel 
CRISPR systems with potential biotechnological applications is occurring at a steady pace. 
Hence, there is a need to improve the performance of CRISPR endonucleases that is robust and 
can be applied easily across CRISPR systems. 
 
The rational design of hp-sgRNAs as characterized in this study is a promising method to meet 
this need. For 5 of the most commonly applied Cas effectors, utilizing well-characterized off-
target sites, we demonstrate that rationally designed RNA secondary structures increase 
specificity by an average of 55-fold. Moreover, despite the widely ranging biochemical 
properties of each Cas effector used, we observe consistent behavior of hp-sgRNAs, where 
CRISPR activity is inhibited as a function of the stability of the secondary structure. 
 
The strategy used in this study was inspired by previous efforts, which aimed to increase 
nuclease specificity by weakening direct interactions between Cas9 and the DNA21,22. While we 
do not directly determine the mechanism of hp-sgRNA-driven specificity increase, we 
hypothesize that it occurs through inhibition of R-loop kinetics, which inhibits the structural 
transitions of the CRISPR endonuclease that are necessary for activity at off-target sites30. The 
evidence for this is threefold. First, using ChIP-qPCR we show that hp-sgRNAs do not decrease 
dCas9 binding at off-target sites, even when nuclease activity is reduced by orders of magnitude 
(Fig. 4e). This is evidence that nuclease activity is diminished by the inhibition of full R-loop 
formation. Second, because RNA–DNA duplexes are regularly accommodated in the central 
binding channel of CRISPR endonucleases, it is likely that RNA–RNA duplexes are similarly 
accommodated without interfering with RNP complex formation. This is supported by evidence 
that sgRNAs with significant spacer secondary structure could readily complex with SpCas949. 
Finally, the predictive power of our kinetic model supports its principle hypothesis: that R-loop 
formation is a kinetic process that is modulated by RNA secondary structures. Collectively, these 
points suggest that sgRNA–endonuclease complex levels are maintained and that observed 
specificity increases are caused by secondary-structure mediated inhibition of R-loop formation, 
limiting the conformation change to an activated endonuclease at off-target sites. 
 
Our study considers R-loop formation as the central process governing CRISPR nuclease 
activity: its modulation allows for more specific genome editing and its modeling facilitates 
predictions of CRISPR activity. Improvements to the modeling of this process would be broadly 
useful for in silico prediction of off-target effects and for designing functional hp-sgRNAs a 
priori. As our model approximates this behavior using thermodynamic parameters of nucleic 
acids derived from in vitro data, further refinement of our understanding of RNA–DNA 
interactions and mispairing within the catalytic environment of different CRISPR endonucleases 
will probably improve its predictive and design performance. Recent methods using massively 
parallel assessment of CRISPR endonuclease binding and catalysis could provide attractive data 
sets for model refinement50,51. 
 
In this study, we demonstrate a method to increase specificity across diverse CRISPR systems. 
Future studies will be useful to determine whether hp-sgRNAs can similarly regulate new Cas12, 
Cas13 or Cas14 effectors4,5,11,52,53. The hp-sgRNA secondary structures that regulate specificity 
may be combined with other methods of sgRNA engineering to modulate activity, specificity and 
orthogonality54,55,56. sgRNA engineering, in conjunction with careful spacer choice and 
optimized gene delivery, could enable higher specificity of CRISPR nucleases for next-
generation genome editing and facilitate realizing the potential of CRISPR for sensitive 
therapeutic and diagnostic applications. 
 
Methods 
 
Plasmids and oligonucleotides 
 
Expression plasmids for the Cas effectors and their respective sgRNAs were obtained through 
Addgene (Addgene catalog nos. 41815, 47108, 65776, 70708, 70709, 78741, 78742, 78743, 
78744); crRNA sequences are listed in Supplementary Table 1 and oligonucleotide sequences are 
found in Supplementary Table 2. To create sgRNA plasmids, oligonucleotides containing the 
target sequences were obtained from IDT, hybridized, phosphorylated and cloned in the 
appropriate plasmids using BbsI or BsmBI sites. 
 
All hp-sgRNA designs were informed through the use of in silico structure determination and 
only spacer sequences were used for these predictions (that is, structural sequences in the 
tracrRNA or crRNAs were excluded)57. 
 
Human cell culture and transfection 
 
HEK293T cells were obtained from the American Tissue Collection Center through the Duke 
University Cancer Center Facilities and were maintained in DMEM supplemented with 10% 
FBS and 1% penicillin-streptomycin at 37 °C with 5% CO2. HEK293T cells were transfected 
with Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Transfection 
efficiencies were routinely higher than 80%, as determined by fluorescence microscopy after 
delivery of a control eGFP expression plasmid. All transfections were performed in 24-well cell 
culture plates that were coated with a 1:10 dilution of poly-L-lysine (P8920 SIGMA). On day 1, 
cell culture plates were coated and 200,000 cells were seeded per well. On day 2, cells were put 
in Opti-MEM and transfected with 800 ng plasmid (600 ng of Cas effector, 200 ng sgRNA) and 
2 µl Lipofectamine 2000. On day 3, medium was changed to DMEM supplemented with 10% 
FBS and 1% penicillin-streptomycin. Cells were collected for downstream analysis on day 5. 
 
Surveyor assays 
 
The region surrounding the sgRNA or crRNA target site was amplified by PCR with the 
AccuPrime PCR kit (Invitrogen) and 50–200 ng of gDNA as template using primers listed in 
Supplementary Table 3. The PCR products were melted and reannealed using the temperature 
program: 95 °C for 180 s, 85 °C for 20 s, 75 °C for 20 s, 65 °C for 20 s, 55 °C for 20 s, 45 °C for 
20 s, 35 °C for 20 s and 25 °C for 20 s with a 0.1 °C s−1 decrease rate in between steps. This 
allows the formation of mutant and wild-type DNA strands with the consequent formation of 
distorted duplex DNA. Without purifying the PCR product, 18 µl of the reannealed duplex was 
combined with 2 µl of the Surveyor nuclease (IDT), which cleaves DNA duplexes at the sites of 
distortions created by either bulges or mismatches, and 1 µl of enhancer solution. This reaction 
was incubated at 42 °C for 60 min and then separated on a 10% TBE polyacrylamide gel. The 
gels were stained with ethidium bromide and quantified using ImageLab (Bio-Rad)58. 
 
Deep sequencing 
 
gDNA was purified from cells using the DNeasy kit (Qiagen). Biological replicates were 
generated from three separate transfections for each experimental condition. On-target and off-
target sites were amplified using 100 ng gDNA with AccuPrime polymerase (Invitrogen). 
Primers are listed in Supplementary Table 3. For some regions, 4% v/v dimethylsulfoxide was 
used in the PCR for efficient amplification. PCR primers included Nextera adapters for binding 
to Illumina flowcells. Using a second round of PCR, group-specific barcodes were added. The 
resulting PCR products were purified using Agencourt AMPure beads (Beckman coulter), 
quantified using Qubit Fluorimeter (Thermo Fisher), pooled and sequenced with 150-base pair 
(bp) paired-end reads on an Illumina MiSeq instrument. CRISPResso was used for sequence 
analysis59. Sequences were first trimmed to remove adapter sequences. Sequences were filtered 
using a minimum average quality score of 30. Reads were trimmed to remove adapter sequences. 
Paired reads were then merged using fast length adjustment of short reads (FLASH) to create a 
single sequence of higher quality; a minimum overlap of 40 bp was used. CRISPRessoPooled 
was then used to demultiplex reads and quantify non-homologous end joining rates. A minimum 
identity score of 80 was used for demultiplexing. Only insertions and deletions were used in 
calling CRISPR-generated non-homologous end joining events, since CRISPR-based gene 
editing largely causes indels and not substitutions. Each biological replicate had a minimum of 
1,500 reads per loci; the average was approximately 20,000 reads per replicate per loci. 
Hypothesis testing was carried out using a one-sided Fisher exact test on the pooled read counts 
of three biological replicates. P values were adjusted for multiple comparisons using the method 
of Benjamini and Hochberg. 
 
RT–qPCR 
 
IL1RN activation experiment 
 
Cells were transfected as described above. RNA was isolated using the RNeasy Plus RNA 
isolation kit (Qiagen). Complementary DNA synthesis was performed using the SuperScript 
VILO cDNA Synthesis Kit (Invitrogen). Real-time PCR using SYBR green Fastmix (Quanta 
BioSciences) was performed with the CFX96 Real-Time PCR Detection System (Bio-Rad) with 
oligonucleotide primers reported in Supplementary Table 3 that were designed using 
Primer3Plus software and purchased from IDT. Primer specificity was confirmed by agarose gel 
electrophoresis and melting curve analysis. Reaction efficiencies over the appropriate dynamic 
range were calculated to ensure linearity of the standard curve. The results are expressed as fold-
increase messenger RNA expression of the gene of interest normalized to GAPDH expression by 
the ΔΔCt method, whereby the difference in cycle number of the control sample is used to 
normalize the difference in cycle number of the experimental sample. 
 
HBG1 and IL1B activation experiments 
 
The day before transfection, HEK293T cells were plated at 105 cells per well in a 96-well plate 
coated with poly-L-lysine. The day of transfection, DMEM was aspirated and 100 μl Opti-MEM 
was added to each well. Each well was then transfected with 400 ng plasmid (300 ng of dCas9-
P300 and 100 ng of sgRNA). Plasmids were brought to 25 μl with Opti-MEM. A separate 
mixture was made of 24.5 μl Opti-MEM and 0.5 μl Lipofectamine 2000, and this was combined 
with the 25-μl plasmid mixture. The 50-μl solution was incubated for 5 min and pipetted slowly 
onto each well. Media was changed the next day to DMEM + 10% FBS + penicillin-
streptomycin. Cells were collected using Cells-to-CT 1-Step TaqMan Kit and TaqMan gene 
expression assays (Thermo Fisher). 
 
Sample-matched 5′ RACE and sgRNA expression measurements 
 
Cells were grown and transfected as described above. Cells were collected using the miRNeasy 
kit (Qiagen) and on-column DNase digestion was performed to rid the sample of any remaining 
plasmid DNA. RNA concentrations were then measured and normalized by dilution. For 
measurement of IL1RN gene activation and sgRNA expression, cDNA was created using 
SuperScript VILO cDNA Synthesis Kit. Primers for the sgRNA RT–qPCR were designed to 
bind the spacer region and end of the sgRNA scaffold. RT–qPCR was carried out as described 
above. 
 
5′ RACE was carried out on the RNA samples using Maxima H Minus reverse transcriptase 
(EP0753, Thermo Fisher). Both the template-switch primer and sgRNA-specific reverse 
transcription primer were ordered from IDT. The reverse transcription primer included a 10-nt 
random barcode that serves as a unique molecular identifier (UMI). Reactions were run using the 
manufacturer protocol with slight modification. Specifically, 1 μg total RNA, 0.2 pmol reverse 
transcription primer, 50 pmol template-switch primer, 1 μl 10 mM dNTP mix and 4 μl 5× reverse 
transcription buffer were combined and brought to 19.5 μl with water. The mixture was 
incubated at 85 °C for 2 min to disrupt RNA secondary structure. The temperature was then 
brought down to 55 °C, 0.5 μl reverse transcriptase was added and the reaction was incubated at 
55 °C for 30 min and terminated by incubating at 85 °C for 5 min. Then 1 μl of each reaction was 
used in a 50-μl PCR to enrich for the desired product, barcode and add i5 and i7 Illumina 
adapters. PCR product was run on an agarose gel to confirm expected product lengths. The 
desired sgRNA cDNAs were purified using a 0.9× bead cleanup (Agencourt AMPure XP Beads, 
Beckman Coulter), concentrations were measured using the high-sensitivity qubit assay and 
samples were pooled and run on an Illumina MiSeq instrument. 
 
Samples were sequenced using 150-bp single-end reads at an average depth of approximately 
100,000 reads per replicate. Any reads without an exact 76-nucleotide sgRNA scaffold sequence 
were discarded. UMI sequences were used to remove any events that might result from PCR 
duplication. After these 2 filters, each sample had an average of 47,675 reads with a minimum of 
8,092. Spacer lengths were then calculated using locations of the sgRNA scaffold and template-
switch sequence as anchors. Finally, the frequency of each observed spacer length was 
determined for each sample. 
 
CIRCLE-seq 
 
CIRCLE-seq libraries were generated largely as previously described60. 
 
Large quantities of HEK293T gDNA were collected as follows: 6 ml NK Lysis Buffer (50 mM 
Tris, 50 mM EDTA, 1% SDS, pH 8) and 30 μl 20 mg ml−1 Proteinase K (QIAGEN 19131) were 
used to resuspend 5 × 107 cells. This lysate was incubated at 55 °C overnight. The next day, 30 μl 
of 10 mg ml−1 RNase A (QIAGEN 19101) was added to the lysed sample. The sample was 
vortexed and incubated at 37 °C for 30 min. Samples were cooled on ice before addition of 2 ml 
prechilled 7.5 M ammonium acetate (Sigma A1542) to precipitate proteins. The samples were 
vortexed, centrifuged at ≥10,000g for 10 min, and the supernatant was carefully decanted into a 
new 15-ml conical tube. Then, 6 ml 100% isopropanol was added to the tube, inverted several 
times and centrifuged at ≥10,000g for 10 min. gDNA was visible as a small white pellet in each 
tube. The supernatant was discarded, and 5 ml freshly prepared 80% ethanol was added to wash 
the pellet and then centrifuged at ≥10,000g for 1 min. The supernatant was carefully discarded, 
and the pellet was air dried for 30 min and finally resuspended in TE buffer. 
 
Approximately 50–100 μg of starting gDNA was needed to generate enough circles for each 
CIRCLE-seq reaction. Using a Diagenode Bioruptor XL sonicator at 4 °C, gDNA was sonicated 
to an average size of approximately 500 bp, with a visible range of 200–1,000 bp, as determined 
by agarose gel electrophoresis. The enzymatic procedure to generate circles was carried out as 
previously described60. For the in vitro digest of the circles, sgRNAs were synthesized from 
Synthego and SpCas9 was purchased from New England Biolabs. Library production was 
carried out as previously described60. Libraries were quantified using a Qubit Fluorimeter 
(Thermo Fisher), pooled and sequenced with 150-bp paired-end reads on an Illumina MiSeq 
instrument. CIRCLE-seq read counts were obtained using previously described methods and 
software43. The following parameters were used for running the CIRCLE-seq pipeline: read 
threshold of 4, window size of 3, mapq threshold of 50, start threshold of 1, gap threshold of 3 
and mismatch threshold of 6. 
 
ChIP-qPCR 
 
Chromatin immunoprecipitation (ChIP) experiments were performed in biological triplicate, 
starting from independent cell transfections, and collected 3 d after transfection. For each 
replicate, 2 × 107 nuclei were resuspended in 1 ml RIPA buffer (1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS in PBS at pH 7.4). Samples were sonicated using a Diagenode 
Bioruptor XL sonicator at 4 °C to fragment chromatin to 200–500-bp segments. Insoluble 
components were removed by centrifugation for 15 min at 15,000 r.p.m. Then, 5 µg of FLAG 
M2 antibody (F1804) was conjugated with sheep anti-mouse IgG magnetic beads (Life 
Technologies, 11203D/11201D). Sheared chromatin in RIPA buffer was then added to the 
antibody-conjugated beads and incubated on a rotator overnight at 4 °C. After incubation, beads 
were washed 5 times with an LiCl wash buffer (100 mM Tris, pH 7.5, 500 mM LiCl, 1% NP-40, 
1% sodium deoxycholate), and remaining ions were removed with a wash in 1 ml TE (10 mM 
Tris-HCl, pH 7.5, 0.1 mM Na2-EDTA) at 4 °C. Chromatin and antibodies were eluted from beads 
by incubation for 1 h at 65 °C in immunoprecipitation elution buffer (1% SDS, 0.1 M NaHCO3) 
followed by overnight incubation at 65 °C to reverse formaldehyde cross-links. DNA was 
purified using MinElute DNA purification columns (Qiagen). qRT–PCR using SYBR green 
Fastmix (Quanta BioSciences) was performed with the CFX96 Real-Time PCR Detection 
System (Bio-Rad) and the oligonucleotide primers reported in Supplementary Table 3. A total of 
100 pg ChIP DNA was loaded into each reaction. The results are expressed as a fold increase of 
signal at the target locus normalized to signal of a region in the β-actin locus using the 
ΔΔCt method. 
 
Kinetic R-loop formation simulations 
 
A first-principles, biophysical simulation of sgRNA invasion of a DNA duplex was performed in 
MATLAB by modeling the processes as a one-dimensional random walk in a position-dependent 
potential29. This was formulated as a continuous-time Markov chain in MATLAB. The position-
dependent potential is determined by the nearest-neighbor-dependent DNA:DNA binding free 
energies61, RNA:DNA binding free energies62 and guide RNA secondary structure free energies 
that are disrupted or restored as invasion progresses/recedes. Here we have generalized the 
model to estimate sgRNA residence time at spacers with arbitrary numbers and species of 
mismatches, and to account for effects of spacer secondary structure on invasion kinetics. 
 
The sgRNA is base paired with the spacer up to spacer site m (2 ≥ m ≥ 20). At each state m, the 
sgRNA is assumed to be in quasi-equilibrium with the DNA, such that at perfectly matched 
spacer sites the forward rate (rate of additional guide RNA invasion; m to m + 1) vf is estimated 
using the symmetric approximation to be exp(−(ΔG°(m + 1)RNA:DNA – ΔG°(m + 1)DNA:DNA –
 ΔG°(m + 1)RNA,SS)/2RT), where R is Boltzmann’s constant, T is the temperature (here 37 °C to 
correspond with the parameter set we used) and the 1/2 corrective term is included to satisfy 
detailed balance. ΔG°(m + 1)RNA:DNA is the free energy of the base pairing between the RNA and 
DNA target at site m + 1. ΔG°(m + 1)DNA:DNA is the free energy of the base pairing between the 
spacer and its complementary DNA strand. ΔG°(m + 1)RNA,SS is the difference in free energies 
between the predicted structures of the 20 − m − 1 uninvaded nucleotides of the sgRNA at 
site m + 1 and the 20 − m uninvaded nucleotides of the sgRNA at site m. The reverse rate vr was 
calculated similarly as exp(−(ΔG°(m − 1)DNA:DNA – ΔG°(m − 1)RNA:DNA + ΔG°(m − 1)RNA,SS)/2RT). 
At m = 1, the sgRNA irreversibly falls off the DNA (m = 1 acts as an absorbing state). RNA 
secondary structure free energy was calculated using the rnafold function in MATLAB63,64. 
 
To estimate transition rates from site m in the presence of mismatched nucleotides, the next 
complementary site n is identified, and ΔG°(n)MM is estimated from the difference in free 
energies between the sgRNA (Rm)–DNA target (Pm) duplex from sites 1 to m and the sgRNA–
DNA target duplex from sites 1 to n. These duplex free energies were calculated using the 
MATLAB rnafold function using the sequence Rm–UUUU–Pm, with a minimum size of the loops 
(in nucleotides) set to 4. The forward rate was then calculated as exp(−(ΔG°(n)MM – Σ(k = 
m+1,n) ΔG°(k)DNA:DNA – ΔG°(k)RNA,SS)/2RT) and similarly for the reverse. 
 
The forward and reverse rates were calculated and assembled into a 19 × 19 Q-matrix (Q)65, and 
the mean lifetimes L of the sgRNA–spacer interaction was calculated as L = –α0Q−11, where 1 is 
a 19-element column vector with values all 1. α0 is a 19-element row vector containing the 
fractional population of initial states (m = 2–20). These experiments were performed for all 16 
sgRNAs and 12,181 ChIP-seq hits using the published data sets from Kuscu et al.41 and Wu et 
al.40. For each sgRNA, log(L) was correlated (Pearson) with log(ChIP-seq count normalized to 
on-target site), and these correlations combined using Fisher’s method. 
 
Protein purification 
 
Plasmids encoding SpCas9 and SaCas9 were transformed into Rosetta 2 (DE3) competent cells. 
Clones were used to inoculate 25-ml starter cultures. Starter cultures were grown overnight, spun 
down and used to inoculate 1-liter cultures. Inoculated 1-liter cultures were grown for 5 h at 
25 °C after which the temperature was dropped to 16 °C and expression induced using 0.1 mM 
isopropylthiogalactoside. Induced cultures were grown for another 12 h at 16 °C. Cells were 
collected by centrifugation at 4,000g and stored at −80 °C for long-term storage. Cell pellets 
were resuspended in 30 ml lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 10 mM MgCl2, 10% 
v/v glycerol, 0.2% Triton-1000, 1 mM PMSF). The cell suspension was lysed by sonication at 
30% duty for 5 min. The suspension was then centrifuged for 30 min at 12,000g. The supernatant 
was then taken and incubated with Ni-NTA resin (Qiagen) for 30 min under gentle agitation. The 
resin was then loaded onto a column, washed with wash buffer (35 mM imidizole, 50 mM Tris-
HCl, 500 mM NaCl, 10 mM MgCl2, 10% v/v glycerol) and eluted with elution buffer (120 mM 
imidizole, 50 mM Tris-HCl, 500 mM NaCl, 10 mM MgCl2, 10% v/v glycerol). Ultracel-30k 
centrifugal filters were then used to exchange solvents to the storage buffer (50 mM Tris-HCl, 
500 mM NaCl, 10 mM MgCl2, 10% v/v glycerol). The samples were then aliquoted and frozen at 
−80 °C. 
 
In vitro digestion 
 
Regions of interest were amplified using PCR from HEK293T gDNA and purified using bead 
purification (Agencourt AMPure XP Beads, Beckman Coulter). Cas9 and sgRNA were 
combined and incubated for 10 min at room temperature at a 1:1 molar ratio. The Cas9–sgRNA 
complex was then combined with DNA at a 10:1 molar excess of RNP in NEB buffer 2.1. The 
reaction was incubated at 37 °C for 1 h after which Gel Loading Dye, Purple (6×) (NEB catalog 
no. B7024S) was added. To fully dissociate Cas9–DNA interactions the reaction was heated to 
90 °C and cooled. The reaction was then resolved on a 2% agarose gel. 
 
AFM 
 
AFM was performed in air as previously described; see ref. 6 for details. Imaging was performed 
using a Bruker Nanoscope V Multimode with RTSEP (Bruker) probes (nominal spring constant, 
40 N m−1; resonance frequency, 300 kHz). Before experiments, protein and guide RNAs were 
mixed at 1:1.5 ratio for 10 min in a buffer designed to limit DNA cleavage but not DNA binding 
(20 mM Tris-HCl (pH 7.5), 100 mM potassium glutamate, 5 mM CoCl2 and 0.4 mM TCEP)66. 
SpCas9 and SaCas9 proteins were purified as described above, AsCas12a was purchased from 
IDT, and all sgRNAs/crRNAs were purchased from Synthego. Protein and DNA were mixed in a 
solution of working buffer for at least 10 min at room temperature, deposited for 8 s on freshly 
cleaved mica (Ted Pella, Inc.) that had been treated with 3-aminopropylsiloxane as previously 
described67, rinsed with ultra-pure (>17 MΩ) water and dried in air. Proteins were centrifuged 
briefly before incubation with DNA. At least three preparations for each experimental condition 
were imaged and analyzed. Images were acquired with pixel resolution of 1,024 × 1,024 over 
2.75-μm2 areas or 2,048 × 2,048 over 5.5-μm2 areas at 1.5 lines per second for each sample. 
Image analysis to determine the distribution of binding sites along the DNA was performed as 
described previously29. Apparent dissociation constants of CRISPR proteins were determined 
using the method pioneered by Yang et al.68, adapted as previously described29. Consensus 
structures of images of CRISPR proteins were determined by performing a reference-free 
alignment as previously described5. 
 
Data availability 
Sequencing data are available through the National Center for Biotechnology Information 
Sequence Read Archive (SRA) database (PRJNA524383), including all deep sequencing, 5′ 
RACE RNA-seq and CIRCLE-seq files. All other relevant raw data are available from the 
corresponding author on reasonable request. 
 
Code availability 
Custom scripts used to analyze 5′ RACE experiments and conduct kinetic modeling are available 
upon reasonable request. 
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Supplementary Figure 1 
Engineered RNA secondary structures tune the activity of dCas9-P300. 
(a,b) Gene activation of HBG1 and IL1B using hp-sgRNAs with varying stem lengths, measured by qRT-PCR. Gene activation is plotted 
as a function of the predicted folding energy of engineered secondary structure for each hp-sgRNA. WT-sgRNA is shown in black, non-
structured-sgRNAs are shown in grey, and hairpin-sgRNAs are shown in blue. Data are shown as fold increase relative to the control 
sample. The control sample was transfected with dCas9-P300 only. The mean is the measure of centre and error bars represent s.e.m. 
for n=3. The sequences of all sgRNAs are listed in Supplementary Table 1.  
 
 
 
 
 
Supplementary Figure 2 
Expression levels and in vivo processing of hairpin- and non-structured- sgRNAs. 
(a) Schema depicting experimental work-flow. Cells were transfected with plasmids encoding dCas9-P300 and sgRNA variants. RNA 
harvested from cells was used to measure gene activation of IL1RN, sgRNA expression levels, and spacer sequence identities. (b) 
Schema depicting 5’ RACE applied specifically to sequence sgRNAs. Template switching of the reverse transcriptase ensures accurate 
profiling of the 5’ ends of sgRNA variants. (c) Gene activation induced by each sgRNA variant. This experiment was performed as 
shown in Figure 1, except that extraction of total RNA, rather than only mRNA, was performed. (d) Replotting the mean of each group in 
(c) as a function of the predicted folding energy of each hp-sgRNA’s engineered secondary structure. (e) Expression level of each 
sgRNA variant as measured by rt-qPCR. (f) Replotting the mean of each hp-sgRNA’s activity in (c) against its mean expression level as 
shown in (e). (g) The distribution of spacer lengths in cells treated with various sgRNA variants, as determined by 5’ RACE followed by 
deep sequencing. The number next to the sgRNA alias indicates the number of nucleotides added to the 5’ end of the spacer (e.g. hp17 
and ns17 have 17 nt added, and a total spacer length of 37 nt). The expected unprocessed length of a sgRNA variant is highlighted in 
an orange box. (h) % of processing to 20nt for each sgRNA variant, as measured by RNA-seq. (i) Replotting the mean of each hp-
sgRNA’s activity in (c) against its mean degree of processing as shown in (i). The mean is the measure of centre and error bars 
represent s.e.m. for n=3. The sequences of all sgRNAs are listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 3. 
Optimizing hairpin structures for VEGFA spacer 1. 
(a) On-target and off-target activity of hairpin variants in human cells, as determined by the Surveyor assay. Hairpins utilize an external 
loop and stems form on the 5’ end of the spacer. (b) Predicted structures of sgRNA variants. (c) On-target activity of hairpin variants in 
human cells, as determined by the Surveyor assay. Hairpins utilize an internal loop and stems form near the 5’ end of the spacer. (d) 
Predicted structures of sgRNA variants. (e) On-target activity of hairpin variants in human cells, as determined by the Surveyor assay. 
Hairpins utilize a truncated spacer, an external loop, and a stem that forms near the 5’ end of the spacer. (f) Predicted structures of 
sgRNA variants.  Representative gels are shown from optimizations that were performed between one and three times. Optimized 
structures were further investigated with deep-sequencing, as shown in Fig. 3 and Supplementary Fig. 6. The sequences of all sgRNAs 
are listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 4 
Optimizing hairpin structures for EMX1 spacer 1. 
(a) On-target and off-target activity of hairpin variants in human cells, as determined by the Surveyor assay. Hairpins utilize an external 
loop and stems form on the 5’ end of the spacer. (b) On-target and off-target activity of hairpin variants in human cells, as determined 
by the Surveyor assay. Hairpins utilize an internal loop and stems form on the 3’ end of the spacer. (c) Predicted structures of sgRNA 
variants. Representative gels are shown from optimizations that were performed between one and three times. Optimized structures 
were further investigated with deep-sequencing, as shown in Fig. 3 and Supplementary Fig. 6. The sequence of all sgRNAs used are 
listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 5 
Optimizing hairpin structures for VEGFA spacer 2. 
(a) On-target and off-target activity of hairpin variants in human cells, as determined by the Surveyor assay. Hairpins utilize an external 
loop and stems form on the 5’ end of the spacer. (b) On-target and off-target activity of hairpin variants in human cells, as determined 
by the Surveyor assay. Hairpins utilize an internal loop and stems form near the 5’ end of the spacer. (c) On-target and off-target 
activity of hairpin variants in human cells, as determined by the Surveyor assay. Hairpin utilizes an external loop, non-canonical base 
pairing, and stems form near the 3’ end of the spacer. (d,e) Predicted structures of sgRNA variants. Representative gels are shown 
from optimizations that were performed between one and three times. Optimized structures were further investigated with deep-
sequencing, as shown in Fig. 3 and Supplementary Fig. 6. The sequences of all sgRNAs used are listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 6 
 
 
Hairpin-sgRNAs increase the specificity of SpCas9 in human cells. 
(a,b,c) On-target and off-target mutation rates for sgRNA variants targeting the EMX1 and VEGFA genes, measured by deep-
sequencing. ‘Percent modified’ indicates percentage of reads mutated when compared to the wild-type loci. Significant differences in 
mutational activity were found at all off-target sites when comparing wild-type sgRNA (‘WT’) to control samples, except for VEGFA 
spacer 2 at OT10 (P  <  0.01, FDR). At all measured off-target sites, hairpin sgRNAs show significant decreases in activity compared 
to that of wild-type sgRNA (P  <  0.05, FDR). Hypothesis testing using a one-sided Fisher exact test with pooled read counts, adjusting 
for multiple comparisons using the Benjamini–Hochberg method. The sequence of all sgRNAs used are listed in Supplementary Table 
1. (d) On-target editing rates for sgRNA variants plotted on a linear scale. (e) Specificity metrics for sgRNA variants. Specificity metric 
defined as on-target indel-rate divided by the sum of all off-target indel-rates. The mean is the measure of centre and error bars 
represent s.e.m. for n=3. Hairpins A, B, and C refer to the respective hairpin sgRNAs characterized in panels a-c and are color 
matched. For example, hairpins A, B and C for spacer VEGFA.1 are hairpins 4, 5, and 6. The sequence of all sgRNAs used are listed in 
Supplementary Table 1. FDR, false discovery rate. 
 
 
 
Supplementary Figure 7 
Unbiased genome-wide detection of off-target activity using CIRCLE-seq. 
(a,b,c,d) Read counts for two replicates were plotted to demonstrate reproducibility of the assay. Activity at the on-target site shown in 
green. The experiment was performed with EMX1 spacer 1 and hairpin-sgRNA 2. Data points clustered along an axis have a 
corresponding read counts of zero but were given a pseudocount for display purposes. 
 
 
 
Supplementary Figure 8 
Comparative genome-wide activity of sgRNA variants applied with SpCas9. 
(a,b,c) Plotting CIRCLE-Seq read counts of WT-sgRNA against truncated-, hairpin-, and non-structured-sgRNAs, respectively. Only 
those off-target sites present in both replicates (Supplementary Figure 7) were used for this analysis. The on-target sites are shown in 
green. Read counts represent the sum of two replicate experiments. The experiment was performed with EMX1 spacer 1 and hairpin-
sgRNA 2. Data points clustered along an axis have a corresponding read count of zero but were given a pseudocount for display 
purposes. (d) Venn diagram representing the overlap of all identified CIRCLE-Seq cleavage sites. For each condition, only sites 
identified in both replicates were used. (e) An UpSetR plot showing the number of sites that overlap between various intersections of 
sample groups. Sample group intersections are indicated by the matrix below. 
 
 
 
 
 
Supplementary Figure 9 
Off-target sites identified by CIRCLE-seq for SpCas9 using EMX1 spacer 1. 
(a,b,c,d) Sequence identity of off-target sites detected using CIRCLE-seq. WT and truncated sgRNAs have truncated listings that are 
continued in Supplementary Figure 11. Brackets indicate the same off-target site that has two same-scoring alignments to the on-target 
site. WT and Tru off-target lists were truncated due to space limitations. 
 
 
 
 
Supplementary Figure 10 
Optimizing hairpin structures for SaCas9-KKH spacers. 
(a,b,c) On-target and off-target activity of hairpin variants in human cells, as determined by the Surveyor assay. Hairpins utilize an 
external loop and stems form on the 5’ end of the spacer. (d,e,f) Predicted structures of sgRNA variants. Representative gels are shown 
from optimizations that were performed between one and three times. Optimized structures were further investigated with deep-
sequencing, as shown in Fig. 6. The sequence of all sgRNAs used are listed in Supplementary Table 1. 
 
 
 
Supplementary Figure 11 
Optimizing hairpin structures for Cas12a spacers. 
Optimizing hairpin structures for LbCas12a. (a,b,c) On-target and off-target activity of hairpin variants in human cells, as determined by 
the Surveyor assay. Hairpins utilize an external loop and stems form on the 5’ end of the spacer. (d,e,f) Predicted structures of sgRNA 
variants. Representative gels are shown from optimizations that were performed between one and three times. Optimized structures 
were further investigated with deep-sequencing, as shown in Fig. 6. The sequence of all sgRNAs used are listed in Supplementary 
Table 1. 
 
 
 
 
Supplementary Figure 12 
RNA secondary structure drives the specificity increases observed with hp-sgRNAs used with SpCas9. 
(a,b,c) Nuclease activity of hp-sgRNAs and corresponding non-structured (n.s.) controls in human cells; sgRNA variants were tested 
with SpCas9, as characterized in Supplementary Fig. 5. Deep sequencing was used to measure gene editing activity. Significant 
differences in mutational activity were found at all off-target sites when comparing wild-type sgRNA (‘WT’) to control samples 
(P  <  0.01 10-129). At all examined off-target sites, hairpin-sgRNAs significantly reduced gene editing activity when compared to wild-
type sgRNA (P  <  0.05 10-14). At all examined off-target (OT) sites, hp-sgRNAs significantly reduced editing activity when compared 
to the corresponding nonstructured-sgRNA, except for VEGFA spacer 1 at OT3 and VEGFA spacer 2 at OT1 and OT2 (P  <  0.05 10-
9
). Hypothesis testing was carried out using a one-sided Fisher exact test with pooled read counts, adjusting for multiple comparisons 
using the Benjamini–Hochberg method. The mean is the measure of centre and error bars represent s.e.m. for n=3. The sequence of 
all sgRNAs used are listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 13 
CRISPR off-target activity as a function of mismatch number and mismatch position. 
(a) The normalized indel activity for off-targets, grouped by the number of mismatches present, as measured by deep sequencing. 
Activity was normalized by the on-target activity of the corresponding WT- or hp- sgRNA. Each data point represents a different off-
target site and is the mean value of editing from three biological replicates. Boxes represent quartiles, the median is the measure of 
centre and n for each group is shown in the panel. Individual points with a normalized indel rate of zero are not shown. (b) The 
positional dependence of mismatches in off-targets identified via CIRCLE-seq, as determined by off-targets shown in Supplementary 
Fig. 9. 
 
 
 
Supplementary Figure 14 
In vitro nuclease activity of Cas9 and Cas12 effectors with engineered sgRNA variants. 
(a,b,c) In vitro digests demonstrating the on-target and off-target activity of sgRNA variants. PCR amplicons containing various target 
sites were incubated with the purified Cas effector complexed with chemically synthesized sgRNAs. EMX1 spacer 1 was applied with 
SpCas9 using hp-sgRNA 2. EMX1 spacer 2 was applied with SaCas9 using hp-sgRNA 4. DNMT1 spacer 1 was applied with AsCas12a 
using hp-sgRNA 4. Each experiment was performed once. The sequence of all sgRNAs used are listed in Supplementary Table 1.  
 
 
 
Supplementary Figure 15 
Single-molecule imaging reveals the effect of sgRNA spacer secondary structure on DNA-binding profiles of CRISPR 
effectors in vitro. 
(a) Example atomic force microscopy (AFM) image of SpCas9 bound to different points on a single, streptavidin-labeled DNA molecule. 
The DNA molecule has a target site and two known off-target sites distributed along its length. OT1 is a designed off-target with 7 
consecutive PAM-distal mismatches. OT2 is an off-target that was validated in human cells by deep-sequencing; it is the off-target with 
the highest mutational rate for the given spacer. (below) Aligned and averaged structures of CRISPR effectors by AFM. At least three 
preparations for each experimental condition were imaged and analyzed. (b,c,d) Normalized binding profiles of (b) SpCas9 (apparent 
dissociation constants Kd at the on-target site for sgRNA: 8.8 ± 0.9 nM (SEM); hp-sgRNA: 10.0 ± 0.9 nM; ns-sgRNA: 2.1 ± 0.1 nM), (c) 
SaCas9 (sgRNA: 5.1 ± 0.4 nM (SEM); hp-sgRNA: 8.7 ± 1.1 nM; ns-sgRNA: 9.0 ± 0.9 nM), and (d) AsCas12a (sgRNA: 5.7 ± 1.2 nM; hp-
sgRNA: 16.9 ± 3.8 nM; ns-sgRNA: 8.9 ± 1.6 nM). (e) A specificity metric for the binding of each sgRNA variant. The metric is defined as 
the frequency of observed DNA molecules bound by Cas9/Cas12a proteins at the on-target site divided by the frequency of observed 
DNA molecules bound by Cas9/Cas12a with no Cas9/Cas12a proteins at the on-target site. The mean is the measure of centre. EMX1 
spacer 1 was applied with SpCas9 using hp-sgRNA 2. EMX1 spacer 2 was applied with SaCas9 using hp-sgRNA 4. DNMT1 spacer 1 
was applied with AsCas12a using hp-sgRNA 4. The sequence of all sgRNAs used are listed in Supplementary Table 1.  
 
Supplementary Table 1, Spacer Sequences Tested in This Study
Cas	Effector Gene	Target Alias Spacer	Sequence Free	Energy,	kcal/mol
SpCas9 IL1RN	site	1 WT GCAUCAAGUCAGCCAUCAGC -0.3
SpCas9 IL1RN	site	1 Hp9 GAUGC AACA GCAUCAAGUCAGCCAUCAGC -6.7
SpCas9 IL1RN	site	1 Hp13 GCUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -12.4
SpCas9 IL1RN	site	1 Hp14 GACUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -16.4
SpCas9 IL1RN	site	1 Hp15 GGACUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -16.1
SpCas9 IL1RN	site	1 Hp16 GUGACUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -17.4
SpCas9 IL1RN	site	1 Hp17 GCUGACUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -23.0
SpCas9 IL1RN	site	1 Hp21 GAUGGCUGACUUGAUGC AACA GCAUCAAGUCAGCCAUCAGC -32.8
SpCas9 IL1RN	site	1 Ns9 GUAUC AAUA GCAUCAAGUCAGCCAUCAGC -0.5
SpCas9 IL1RN	site	1 Ns13 GUCGAUAUC AAUA GCAUCAAGUCAGCCAUCAGC -0.7
SpCas9 IL1RN	site	1 Ns17 GUCGAUCAGUAUC AAUA GCAUCAAGUCAGCCAUCAGC -0.9
SpCas9 IL1RN	site	1 Ns21 GCAGUUCAGUCAGUAUC AAUA GCAUCAAGUCAGCCAUCAGC -0.7
SpCas9 HBG1	site	1 WT GGCUAGGGAUGAAGAAUAAA 0.0
SpCas9 HBG1	site	1 Hp8 GGCC AACA GGCUAGGGAUGAAGAAUAAA -4.0
SpCas9 HBG1	site	1 Hp10 GUAGCC AACA GGCUAGGGAUGAAGAAUAAA -6.6
SpCas9 HBG1	site	1 Hp12 GCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -11.7
SpCas9 HBG1	site	1 Hp13 GCCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -14.4
SpCas9 HBG1	site	1 Hp15 GAUCCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -17.4
SpCas9 HBG1	site	1 Hp17 GUCAUCCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -21.4
SpCas9 HBG1	site	1 Hp19 GCUUCAUCCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -24.3
SpCas9 HBG1	site	1 Hp23 GUAUUCUUCAUCCCUAGCC AACA GGCUAGGGAUGAAGAAUAAA -29.2
SpCas9 HBG1	site	1 Ns17 GACAAAAGAGACG AAAA GGCUAGGGAUGAAGAAUAAA 0.0
SpCas9 HBG1	site	1 Ns19 GGAACAAAAGAGACG AAAA GGCUAGGGAUGAAGAAUAAA 0.0
SpCas9 HBG1	site	1 Ns23 GAUAAGAAAACAAGAGACG AAAA GGCUAGGGAUGAAGAAUAAA 0.0
SpCas9 IL1B	site	1 WT G AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 IL1B	site	1 Hp11 GUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -3.6
SpCas9 IL1B	site	1 Hp12 GCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -9.4
SpCas9 IL1B	site	1 Hp15 GUCGCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -13
SpCas9 IL1B	site	1 Hp16 GCUCGCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -15.2
SpCas9 IL1B	site	1 Hp17 GCCUCGCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -18.1
SpCas9 IL1B	site	1 Hp19 GUCCCUCGCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -22.8
SpCas9 IL1B	site	1 Hp23 GUUUCUCCCUCGCUGUUUUC AACA AAAAACAGCGAGGGAGAAAC -29.7
SpCas9 IL1B	site	1 Ns11 GACAUACU AACA AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 IL1B	site	1 Ns15 GAUAGACAAAAA AACA AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 IL1B	site	1 Ns17 GGGAAAGACAUACU AACA AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 IL1B	site	1 Ns19 GACGGAAAGACAUACU AACA AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 IL1B	site	1 Ns23 GAAACAGGGAAUCACAUACU AACA AAAAACAGCGAGGGAGAAAC 0.0
SpCas9 EMX1	site	1 WT GAGUCCGAGCAGAAGAAGAA 0.0
SpCas9 EMX1	site	1 Tru GUCCGAGCAGAAGAAGAA 0.0
SpCas9 EMX1	site	1 Hp1 GCUCGGACUC UUCG GAGUCCGAGCAGAAGAAGAA -20.9
SpCas9 EMX1	site	1 Hp2 GGACUC UUCG GAGUCCGAGCAGAAGAAGAA -11.5
SpCas9 EMX1	site	1 Hp3 GCGG GAGUCCGAGCAGAAGAAGAA -2.8
SpCas9 EMX1	site	1 Hp4 GUCGG GAGUCCGAGCAGAAGAAGAA -4.8
SpCas9 EMX1	site	1 Hp5 GCUCGG GAGUCCGAGCAGAAGAAGAA -10.6
SpCas9 EMX1	site	1 Hp6 GGAC UUCG GUCCGAGCAGAAGAAGAA -7.5
SpCas9 EMX1	site	1 Hp7 GCGGAC UUCG GUCCGAGCAGAAGAAGAA -9.1
SpCas9 EMX1	site	1 Ns2 GUAAUG AAUA GAGUCCGAGCAGAAGAAGAA -0.1
SpCas9 VEGFA	site	1 WT GGUGAGUGAGUGUGUGCGUG -1.2
SpCas9 VEGFA	site	1 Tru GAGUGAGUGUGUGCGUG -1.2
SpCas9 VEGFA	site	1 Hp1 GACC UUCG GGUGAGUGAGUGUGUGCGUG -5.8
SpCas9 VEGFA	site	1 Hp2 GCACC UUCG GGUGAGUGAGUGUGUGCGUG -7.6
SpCas9 VEGFA	site	1 Hp3 GUCACC UUCG GGUGAGUGAGUGUGUGCGUG -9.1
SpCas9 VEGFA	site	1 Hp4 GCACG UUCG GGUGAGUGAGUGUGUGCGUG -7.4
SpCas9 VEGFA	site	1 Hp5 GUACG UUCG GGUGAGUGAGUGUGUGCGUG -5.1
SpCas9 VEGFA	site	1 Hp6 GCAUG UUCG GGUGAGUGAGUGUGUGCGUG -5.3
SpCas9 VEGFA	site	1 Ns4 GAGGAGUUA GGUGAGUGAGUGUGUGCGUG -1.2
SpCas9 VEGFA	site	2 WT GGGUGGGGGGAGUUUGCUCC -3.8
SpCas9 VEGFA	site	2 Tru GUGGGGGGAGUUUGCUCC -3.4
SpCas9 VEGFA	site	2 Hp1 GCCCCCCACCC UUCG GGGUGGGGGGAGUUUGCUCC -24.0
SpCas9 VEGFA	site	2 Hp2 GCCACCC UUCG GGGUGGGGGGAGUUUGCUCC -15.4
SpCas9 VEGFA	site	2 Hp3 GCCCC GGGUGGGGGGAGUUUGCUCC -8.7
SpCas9 VEGFA	site	2 Hp4 GCCC GGGUGGGGGGAGUUUGCUCC -7.1
SpCas9 VEGFA	site	2 Hp5 GCAUCC UUCG GUGUGGGGGGAGUUUGCUCC -8.5
SpCas9 VEGFA	site	2 Ns4 GUGC GUGUGGGGGGAGUUUGCUCC -3.5
SaCas9 EMX1	site	2 WT GGGCCUCCCCAAAGCCUGGCCA -6.6
SaCas9 EMX1	site	2 Tru	20	nt GGCCUCCCCAAAGCCUGGCCA -6.6
SaCas9 EMX1	site	2 Tru	19	nt GCCUCCCCAAAGCCUGGCCA -2.8
SaCas9 EMX1	site	2 Tru	18	nt GCUCCCCAAAGCCUGGCCA -2.0
SaCas9 EMX1	site	2 Hp1 GCC UUCG GGCCUCCCCAAAGCCUGGCCA -7.6
SaCas9 EMX1	site	2 Hp2 GGCC UUCG GGCCUCCCCAAAGCCUGGCCA -11.4
SaCas9 EMX1	site	2 Hp3 GGGCC UUCG GGCCUCCCCAAAGCCUGGCCA -11.4
SaCas9 EMX1	site	2 Hp4 GAGGCC UUCG GGCCUCCCCAAAGCCUGGCCA -14.2
SaCas9 EMX1	site	2 Ns4 GACCAU AAUA GGCCUCCCCAAAGCCUGGCCA -6.8
SaCas9-KKH EMX1	site	3 WT GUGUGGUUCCAGAACCGGAGGA -3.5
SaCas9-KKH EMX1	site	3 Tru	21	nt GGUGGUUCCAGAACCGGAGGA -3.5
SaCas9-KKH EMX1	site	3 Tru	20	nt GUGGUUCCAGAACCGGAGGA -3.5
SaCas9-KKH EMX1	site	3 Tru	19	nt GGGUUCCAGAACCGGAGGA -3.5
SaCas9-KKH EMX1	site	3 Hp1 GCACAC UUCG GUGUGGUUCCAGAACCGGAGGA -11.3
SaCas9-KKH EMX1	site	3 Hp2 GCCACAC UUCG GUGUGGUUCCAGAACCGGAGGA -13.3
SaCas9-KKH EMX1	site	3 Hp3 GACCACAC UUCG GUGUGGUUCCAGAACCGGAGGA -15.0
SaCas9-KKH EMX1	site	3 Hp4 GAACCACAC UUCG GUGUGGUUCCAGAACCGGAGGA -15.7
SaCas9-KKH EMX1	site	3 Hp5 GGAACCACAC UUCG GUGUGGUUCCAGAACCGGAGGA -19.5
SaCas9-KKH EMX1	site	3 Ns GUAAUGUG AAGC GUGUGGUUCCAGAACCGGAGGA -4.7
SaCas9-KKH EMX1	site	4 WT GCUCAGCCUGAGUGUUGAGGC -6.0
SaCas9-KKH EMX1	site	4 Tru	20	nt GUCAGCCUGAGUGUUGAGGC -4.3
SaCas9-KKH EMX1	site	4 Tru	19	nt GCAGCCUGAGUGUUGAGGC -4.3
SaCas9-KKH EMX1	site	4 Tru	18	nt GAGCCUGAGUGUUGAGGC -4.3
SaCas9-KKH EMX1	site	4 Hp1 GAGC AACA GCUCAGCCUGAGUGUUGAGGC -9.7
SaCas9-KKH EMX1	site	4 Hp2   GUGAGC AACA GCUCAGCCUGAGUGUUGAGGC -10
SaCas9-KKH EMX1	site	4 Hp3  GCUGAGC AACA GCUCAGCCUGAGUGUUGAGGC -11.6
SaCas9-KKH EMX1	site	4 Hp4 GGCUGAGC AACA GCUCAGCCUGAGUGUUGAGGC -14.9
SaCas9-KKH EMX1	site	4 Ns GAUA AACA GCUCAGCCUGAGUGUUGAGGC -6.0
SaCas9-KKH EMX1	site	5 WT GCAACCACAAACCCACGAGGG -2.8
SaCas9-KKH EMX1	site	5 Tru	20	nt GAACCACAAACCCACGAGGG -2.8
SaCas9-KKH EMX1	site	5 Tru	19	nt GACCACAAACCCACGAGGG -2.8
SaCas9-KKH EMX1	site	5 Tru	18	nt GCCACAAACCCACGAGGG -2.8
SaCas9-KKH EMX1	site	5 Hp1 GUGC AACA GCAACCACAAACCCACGAGGG -5.5
SaCas9-KKH EMX1	site	5 Hp2 GUUGC AACA GCAACCACAAACCCACGAGGG -8.34
SaCas9-KKH EMX1	site	5 Hp3 GGUUGC AACA GCAACCACAAACCCACGAGGG -12.1
SaCas9-KKH EMX1	site	5 Hp4 GUGGUUGU AACA GCAACCACAAACCCACGAGGG -14.5
SaCas9-KKH EMX1	site	5 Ns GAUA AACA GCAACCACAAACCCACGAGGG -2.8
SaCas9-KKH FANCF	site	1 WT GCAAGGCCCGGCGCACGGUGG -3.7
SaCas9-KKH FANCF	site	1 Tru	20	nt GAAGGCCCGGCGCACGGUGG -3.7
SaCas9-KKH FANCF	site	1 Tru	19	nt GAGGCCCGGCGCACGGUGG -3.7
SaCas9-KKH FANCF	site	1 Tru	18	nt GGGCCCGGCGCACGGUGG -3.7
SaCas9-KKH FANCF	site	1 Hp1 GUGC AACA GCAAGGCCCGGCGCACGGUGG -6.4
SaCas9-KKH FANCF	site	1 Hp2 GUUGC AACA GCAAGGCCCGGCGCACGGUGG -7.3
SaCas9-KKH FANCF	site	1 Hp3 GCUUGC AACA GCAAGGCCCGGCGCACGGUGG -9.5
SaCas9-KKH FANCF	site	1 Hp4 GCCUUGC AACA GCAAGGCCCGGCGCACGGUGG -14.0
SaCas9-KKH FANCF	site	1 Ns GAUA AACA GCAAGGCCCGGCGCACGGUGG -3.7
AsCas12a DNMT	site	1 WT CUGAUGGUCCAUGUCUGUUA -1.8
AsCas12a DNMT	site	1 Tru	19	nt CUGAUGGUCCAUGUCUGUU -1.8
AsCas12a DNMT	site	1 Tru	18	nt CUGAUGGUCCAUGUCUGU -1.8
AsCas12a DNMT	site	1 Tru	17	nt CUGAUGGUCCAUGUCUG -1.8
AsCas12a DNMT	site	1 Hp1 CUGAUGGUCCAUGUCUGUUA  AGAC -3.0
AsCas12a DNMT	site	1 Hp2 CUGAUGGUCCAUGUCUGUUA  AGACAU -6.0
AsCas12a DNMT	site	1 Hp3 CUGAUGGUCCAUGUCUGUUA  AGACAUGG -10.5
AsCas12a DNMT	site	1 Hp4 CUGAUGGUCCAUGUCUGUUA  AGACAUGGAC -14.8
AsCas12a DNMT	site	1 Ns3 CUGAUGGUCCAUGUCUGUUA  CUCUGCUC -1.8
AsCas12a DNMT	site	1 Ns4 CUGAUGGUCCAUGUCUGUUA  CUCUGCUCAA -1.8
AsCas12a-RVR RPL32P3	site	1 WT GGGUGAUCAGACCCAACAGC -6.1
AsCas12a-RVR RPL32P3	site	1 Tru	19	nt GGGUGAUCAGACCCAACAG -6.1
AsCas12a-RVR RPL32P3	site	1 Tru	18	nt GGGUGAUCAGACCCAACA -6.1
AsCas12a-RVR RPL32P3	site	1 Tru	17	nt GGGUGAUCAGACCCAAC -6.1
AsCas12a-RVR RPL32P3	site	1 Hp1 GGGUGAUCAGACCCAACAGC UUCG GCUGUUGGGU -20.2
AsCas12a-RVR RPL32P3	site	1 Hp2 GGGUGAUCAGACCCAACAGC UUCG GCUGUUGGGUCUGA -26.5
AsCas12a-RVR RPL32P3	site	1 Hp3 GGGUGAUCAGACCCAACAGC UUCG GCUGUUGGGUCUGAUCAC -33.0
AsCas12a-RVR RPL32P3	site	1 Ns3 GGGUGAUCAGACCCAACAGC UUAC AGACAACCCAGACUAGUG -6.1
LbCas12a DNMT	site	1 WT CUGAUGGUCCAUGUCUGUUA  -1.8
LbCas12a DNMT	site	1 Tru	17	nt CUGAUGGUCCAUGUCUG  -1.8
LbCas12a DNMT	site	1 Hp1 CUGAUGGUCCAUGUCUGUUA  AGACAUGGACCA -19.8
LbCas12a DNMT	site	1 Hp2 CUGAUGGUCCAUGUCUGUUA  AGACAUGGACCAUC -22.7
LbCas12a POLQ	site	1 WT GGCAUGAAUUAUAAUGCUGU -4.0
LbCas12a POLQ	site	1 Tru	19	nt GGCAUGAAUUAUAAUGCUG -4.0
LbCas12a POLQ	site	1 Tru	18	nt GGCAUGAAUUAUAAUGCU -4.0
LbCas12a POLQ	site	1 Tru	17	nt GGCAUGAAUUAUAAUGC -2.8
LbCas12a POLQ	site	1 Hp1 GGCAUGAAUUAUAAUGCUGU AACA ACAGC -5.1
LbCas12a POLQ	site	1 Hp2 GGCAUGAAUUAUAAUGCUGU AACA ACAGCAUUAU -10.9
LbCas12a POLQ	site	1 Hp3 GGCAUGAAUUAUAAUGCUGU AACA ACAGCAUUAUAAUUC -16.8
LbCas12a POLQ	site	1 Hp4 GGCAUGAAUUAUAAUGCUGU AACA ACAGCAUUAUAAUUCA -18.9
LbCas12a POLQ	site	1 Hp5 GGCAUGAAUUAUAAUGCUGU AACA ACAGCAUUAUAAUUCAUG -21.5
LbCas12a POLQ	site	1 Hp6 GGCAUGAAUUAUAAUGCUGU AACA ACAGCAUUAUAAUUCAUGCC -27.6
LbCas12a POLQ	site	1 Ns6 GGCAUGAAUUAUAAUGCUGU AACA AUUAUCAAUAUUAAGCUAUG -4.0
LbCas12a IL12A-AS	site	1 WT GGAUGCCACUAAAAGGGAAA -1.2
LbCas12a IL12A-AS	site	1 Tru	19	nt GGAUGCCACUAAAAGGGAA -1.2
LbCas12a IL12A-AS	site	1 Tru	18	nt GGAUGCCACUAAAAGGGA -1.2
LbCas12a IL12A-AS	site	1 Tru	17	nt GGAUGCCACUAAAAGGG -0.8
LbCas12a IL12A-AS	site	1 Tru	16	nt GGAUGCCACUAAAAGG -0.5
LbCas12a IL12A-AS	site	1 Hp1 GGAUGCCACUAAAAGGGAAA AACA UUUCC -3.4
LbCas12a IL12A-AS	site	1 Hp2 GGAUGCCACUAAAAGGGAAA AACA UUUCCCUUUUA -11.9
LbCas12a IL12A-AS	site	1 Hp3 GGAUGCCACUAAAAGGGAAA AACA UUUCCCUUUUAGUGG -20.0
LbCas12a IL12A-AS	site	1 Hp4 GGAUGCCACUAAAAGGGAAA AACA UUUCCCUUUUAGUGGC -23.2
LbCas12a IL12A-AS	site	1 Hp5 GGAUGCCACUAAAAGGGAAA AACA UUUCCCUUUUAGUGGCAU -26.3
LbCas12a IL12A-AS	site	1 Hp6 GGAUGCCACUAAAAGGGAAA AACA UUUCCCUUUUAGUGGCAUCC -31.1
LbCas12a IL12A-AS	site	1 Ns5 GGAUGCCACUAAAAGGGAAA AACA AACAUAGAAUAACACACAUA -1.2
Supplementary Table 2, Primer Sequences Used in This Study
Primer Name Sequence Assay
IL1RN FWD GGAATCCATGGAGGGAAGAT RT-qPCR
IL1RN REV TGTTCTCGCTCAGGTCAGTG RT-qPCR
GAPDH FWD CAATGACCCCTTCATTGACC RT-qPCR
GAPDH REV TTGATTTTGGAGGGATCTCG RT-qPCR
HBG1, TaqMan G.E. Assay Catalog # 4453320 Assay ID: Hs00361131_g1 RT-qPCR
IL1B, , TaqMan G.E. Assay Catalog # 4453320, Assay ID: Hs01555410_m1 RT-qPCR
sgRNA FWD GCATCAAGTCAGCCATCAGC RT-qPCR
sgRNA REV GTGGCACCGAGTCGGTGC RT-qPCR
EMX1.1_OnTar_FWD GGGCCTCCTGAGTTTCTCAT Surveyor
EMX1.1_OnTar_REV GTTGCCCACCCTAGTCATTG Surveyor
EMX1.1_OT1_FWD TCTCTCCTTCAACTCATGACCAGCT Surveyor
EMX1.1_OT1_REV ATCTGCACATGTATGTACAGGAGTCAT Surveyor
VEGFA_Ontar_FWD TCCAGATGGCACATTGTCAG Surveyor
VEGFA_OnTar_REV AGGGAGCAGGAAAGTGAGGT Surveyor
VEGFA.1_OT1_FWD GAGGGGGAAGTCACCGACAA Surveyor
VEGFA.1_OT1_REV TACCCGGGCCGTCTGTTAGA Surveyor
VEGFA.1_OT4_FWD TGTGGAGGGTGGGACCTGGT Surveyor
VEGFA.1_OT4_REV ACAGTGAGGTGCGGTCTTTGGG Surveyor
VEGFA.2_OT1_FWD ACCCCACAGCCAGGTTTTCA Surveyor
VEGFA.2_OT1_REV GAATCACTGCACCTGGCCATC Surveyor
VEGFA.2_OT2_FWD GCCCATTCTTTTTGCAGTGGA Surveyor
VEGFA.2_OT2_REV GAGAGCAAGTTTGTTCCCCAGG Surveyor
EMX1.2_OnTar_FWD CTAGGGTGGGCAACCACAAA Surveyor
EMX1.2_OnTar_REV AGGGAGATTGGAGACACGGA Surveyor
EMX1.2_OT1_FWD CGTCCCCTTTTGGGGAGAGA Surveyor
EMX1.2_OT1_REV GACATGAGTGGTTGTTGCGA Surveyor
EMX1.3_OnTar_FWD GGGCCTCCTGAGTTTCTCAT Surveyor
EMX1.3_OnTar_REV GTTGCCCACCCTAGTCATTG Surveyor
EMX1.3_OT1_FWD GCGTCTTCTCTTCCTCGTCC Surveyor
EMX1.3_OT1_REV GCGCCTGAGAACTGCTTACA Surveyor
EMX1.4_OnTar_FWD GAGGAGCTAGGATGCACAGC Surveyor
EMX1.4_OnTar_REV CACCGGTTGATGTGATGGGA Surveyor
EMX1.4_OT1_FWD ATCTCTCTCAGCCCCTGGTT Surveyor
EMX1.4_OT1_REV GGCGCCTCTGAACATTCAAC Surveyor
EMX1.5_OnTar_FWD GGGCCTCCTGAGTTTCTCAT Surveyor
EMX1.5_OnTar_REV AGGGAGATTGGAGACACGGA Surveyor
FANCF.1_Ontar_FWD GGGCCTGGAAGTTCGCTAAT Surveyor
FANCF.1_Ontar_REV AGGCGTATCATTTCGCGGAT Surveyor
FANCF.1_OT1_FWD GTTGCGTTTGAGGATGAGCA Surveyor
FANCF.1_OT1_REV GAAATCTCCCACGAGTCTCCG Surveyor
POLQ.1_OnTar_FWD GCTGCCAAGGAAAACAGATG Surveyor
POLQ.1_OnTar_REV CCAAGCAAAGTACTGAAATGCTA Surveyor
POLQ.1_OT1_FWD CCCCAAGTGTAGTGCTGAAG Surveyor
POLQ.1_OT1_REV TCCAACCAGCAGTACATGAAG Surveyor
IL12A-AS.1_Ontar_FWD TGAAAAGGTGTTGCTTATTGCCC Surveyor
IL12A-AS.1_Ontar_REV AGCTCAAAAGAAACACGTGAGATT Surveyor
IL12A-AS.1_OT1_FWD AGGGTGGAACAGAGGAGGAA Surveyor
IL12A-AS.1_OT1_REV CAAGACCAGGAAGGAGGCTG Surveyor
RPL32P3.1_OnTar_FWD GTGGCTGTAGATGGGTCCTT Surveyor
RPL32P3.1_OnTar_REV TCACCACCTGTTTGTTGCAG Surveyor
RPL32P3.1_OT1_FWD TGGCCTCCACATTCTTACCA Surveyor
RPL32P3.1_OT1_REV GCTGGATGGCGTCACATTAG Surveyor
RPL32P3.1_OT2_FWD GTTCTTGTGGGTTGACTGGG Surveyor
RPL32P3.1_OT2_REV CTTCACAGCCTCCACGATTG Surveyor
DNMT1.1_OnTar_FWD CTGGGACTCAGGCGGGTCAC Surveyor
DNMT1.1_OnTar_REV CCTCACACAACAGCTTCATGTCAGC Surveyor
DNMT1.1_OT1_FWD TTCTACCTTTCCCATCCCGG Surveyor
DNMT1.1_OT1_REV AGCATGGAGGAGAGGCAATT Surveyor
EMX1.1_OnTar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGTTTCTCATCTGTGCCCCT Deep Sequencing
EMX1.1_OnTar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG     ATCGATGTCCTCCCCATTGG Deep Sequencing
EMX1.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  CGCTTGTCCATGTCTAGGAA Deep Sequencing
EMX1.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TGGCATGGCAAGACAGATTG Deep Sequencing
EMX1.1_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  TTGAAATCTCACCTGGGCGA Deep Sequencing
EMX1.1_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TGGCTTTCACAAGGATGCAG Deep Sequencing
EMX1.1_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   CGAGAAGGAGGTGCAGGAG Deep Sequencing
EMX1.1_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  CCTCGTCCTGCTCTCACTTA Deep Sequencing
EMX1.1_OT4_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  ATAATAATGTCCCTGCCCGG Deep Sequencing
EMX1.1_OT4_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  GCCCAGCTGTGCATTCTATC Deep Sequencing
EMX1.1_OT5_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   CCACAGCGAGGAGTGACA Deep Sequencing
EMX1.1_OT5_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG CTAGTCTAACTCCCGGGCTG Deep Sequencing
EMX1.1_OT6_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GGAATGCCAGTTCTGGGTTG Deep Sequencing
EMX1.1_OT6_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  AGTCATACCTTGGCCCTTCC Deep Sequencing
VEGFA.1_OnTar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  AGCCCATTCCCTCTTTAGCC Deep Sequencing
VEGFA.1_OnTar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  GGAGTGACCCCTGGCCTT Deep Sequencing
VEGFA.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   TATCGCTCATTTCCTACGGC Deep Sequencing
VEGFA.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG GCAGTGAGGAGGTGGTTCTT Deep Sequencing
VEGFA.1_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   TTCAGGGTGTGCAATGTGA Deep Sequencing
VEGFA.1_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   TTCTGGGAATCTAATGTATGGCA Deep Sequencing
VEGFA.1_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   AGATGATCCGCTGGCCTC Deep Sequencing
VEGFA.1_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  CAGAGGTGGAGACTGGGC Deep Sequencing
VEGFA.1_OT4_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  TTGGATCATACGGCCGGTTT Deep Sequencing
VEGFA.1_OT4_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  AAAGTTTCACATGGTTGCGG Deep Sequencing
VEGFA.1_OT5_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GTTCACTCGGCTACAGGGAG Deep Sequencing
VEGFA.1_OT5_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  ATAAGGGGCAAGTTCTGGGC Deep Sequencing
VEGFA.1_OT6_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   GGATGGTGGATTCTGGGCA Deep Sequencing
VEGFA.1_OT6_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TCACACCCACACCCTCATAC Deep Sequencing
VEGFA.1_OT7_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  TTGCTGTGTCTTCCTTCTGC Deep Sequencing
VEGFA.1_OT7_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  AGCTGTATGTGAGTCCCTGA Deep Sequencing
VEGFA.1_OT8_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  CCCCATTGCCTAGAAGAGTCA Deep Sequencing
VEGFA.1_OT8_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  AACCCTTGGGAATCTATCTTGAA Deep Sequencing
VEGFA.1_OT9_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   AGGTGCTTTGCTTATAGATCTGG Deep Sequencing
VEGFA.1_OT9_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCACAGAAAAGGAGGCAAGG Deep Sequencing
VEGFA.1_OT10_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   AGACCCAGTTCCAAGCCAG Deep Sequencing
VEGFA.1_OT10_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TCTCCGGAAGTGCCTTGC Deep Sequencing
VEGFA.1_OT11_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGCACCCTTGACGTCTGG Deep Sequencing
VEGFA.1_OT11_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  AGCTCACCTTCCAGTTCCG Deep Sequencing
VEGFA.1_OT12_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   AGACGTTAACCCCAGCCG Deep Sequencing
VEGFA.1_OT12_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  GGGTAGATGTGGGAAAGGGG Deep Sequencing
VEGFA.1_OT13_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   GTCTCCAGGCCACAGAGTAG Deep Sequencing
VEGFA.1_OT13_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCACCCCAACACCTACATCT Deep Sequencing
VEGFA.1_OT14_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GCTTTTAAATTTATTTCACAATGGT Deep Sequencing
VEGFA.1_OT14_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TTGTGACTTGTTCCATTGTC Deep Sequencing
VEGFA.1_OT15_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    ACCCACTGTTGATATGCCCA Deep Sequencing
VEGFA.1_OT15_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    ATGTATGTGTGTCCGTGGGT Deep Sequencing
VEGFA.1_OT16_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  ACCCCACTGTTCTTAGATGCA Deep Sequencing
VEGFA.1_OT16_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   CGGATTCAGAGGACAGGACA Deep Sequencing
VEGFA.1_OT17_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   AATACAAACTCACCCGCTGC Deep Sequencing
VEGFA.1_OT17_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   GGTTGCACGCTGTACTCG Deep Sequencing
VEGFA.1_OT18_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TGCATTCAACTAATCACTGGCT Deep Sequencing
VEGFA.1_OT18_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG     CTGTTGGGGTTATTTGCATTGC Deep Sequencing
VEGFA.1_OT19_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GAAGGGGAAAGACGGAGGAA Deep Sequencing
VEGFA.1_OT19_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TCTGCCAGATCCTTAGGCG Deep Sequencing
VEGFA.1_OT20_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGAAGCCTGGATCTGCAGAG Deep Sequencing
VEGFA.1_OT20_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   AGAGATGTGTGGCTGTGTCA Deep Sequencing
VEGFA.1_OT21_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   GGGGCCTGACACAAGAAGG Deep Sequencing
VEGFA.1_OT21_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   TGCCTGGATTATGAGAAAAGCTG Deep Sequencing
VEGFA.2_OnTar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  ATGAAGCAACTCCAGTCCCA Deep Sequencing
VEGFA.2_OnTar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  ACACGTCCTCACTCTCGAAG Deep Sequencing
VEGFA.2_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  TCCTATTTACACAGCAGACCCA Deep Sequencing
VEGFA.2_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  CACCTGGCCATCATCCTTCT Deep Sequencing
VEGFA.2_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  TCCTGCAGCTGTACCGTAC Deep Sequencing
VEGFA.2_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   TGCCTTCATTGCTTAAAAGTGGA Deep Sequencing
VEGFA.2_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   TCCATGGAGTGTTCTGCCTG Deep Sequencing
VEGFA.2_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  GCGTCAACCAGAAACACTCA Deep Sequencing
VEGFA.2_OT4_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GGCAACTTCAGACAACCGAG Deep Sequencing
VEGFA.2_OT4_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TCAGAGGGACCTGGGCAG Deep Sequencing
VEGFA.2_OT5_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   ACTTCTTGGGCAGTGATGGA Deep Sequencing
VEGFA.2_OT5_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  ATGGCATTCTCCTGGGTGTG Deep Sequencing
VEGFA.2_OT6_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG   GGAAGACCGTGGAAAGCCC Deep Sequencing
VEGFA.2_OT6_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   CCCCTGTTGGTAGCACAGT Deep Sequencing
VEGFA.2_OT7_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CTCTGGGTCCTCTCTGATGG Deep Sequencing
VEGFA.2_OT7_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   AGGGCAGCTGTGGAATGTAG Deep Sequencing
VEGFA.2_OT8_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GGTTGTGTCCTAATTTGGCCA Deep Sequencing
VEGFA.2_OT8_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  GGCAGAAGGAATTGAGTGATCA Deep Sequencing
VEGFA.2_OT9_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  GCAAAGCTAAGCAGAGATGC Deep Sequencing
VEGFA.2_OT9_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG   CTTCCAGAGCAAACATAGTCCA Deep Sequencing
VEGFA.2_OT10_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG  CCCACCATCGTCACAGGA Deep Sequencing
VEGFA.2_OT10_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG  TCAGAGCAAGAGAGATTTACACA Deep Sequencing
EMX1.2_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CTTGTCCCTCTGTCAATGGCG Deep Sequencing
EMX1.2_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CTAGGGTGGGCAACCACAAAC Deep Sequencing
EMX1.2_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CGATTGGTGGATTCTGTCCCTG Deep Sequencing
EMX1.2_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GTCCCCTTTTGGGGAGAGACC Deep Sequencing
EMX1.2_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGAAGATTTCAGATGCCAAACTGC Deep Sequencing
EMX1.2_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    AAACCTGATCTGTGCTCCG Deep Sequencing
EMX1.2_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GCTTGGGGAACAGGGTCAAT Deep Sequencing
EMX1.2_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CTCTCCTGAGTTGCTGTGGG Deep Sequencing
EMX1.3_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GAGTGTTGAGGCCCCAGTG Deep Sequencing
EMX1.3_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CACCGGTTGATGTGATGGGA Deep Sequencing
EMX1.3_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AACAAGTACCTTTGCAGACCCC Deep Sequencing
EMX1.3_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TCGGAGTCCTCAAGGCTTTTAC Deep Sequencing
EMX1.3_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CAGCCGGTATCAGACCTTGG Deep Sequencing
EMX1.3_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCTCCCGGCAGTTTATCCTT Deep Sequencing
EMX1.3_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TATCTGACTCGTAAGCGGCG Deep Sequencing
EMX1.3_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CCGCTCCAGCTTCTGTTTCT Deep Sequencing
EMX1.4_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG CTGCCATCCCCTTCTGTGAA Deep Sequencing
EMX1.4_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG TCCAGCTTCTGCCGTTTGTA Deep Sequencing
EMX1.4_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CCTGGGTCTCAGTTTTCCCA Deep Sequencing
EMX1.4_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    ACTCAGCCAAGTACAGCAGC Deep Sequencing
EMX1.4_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TTTTGCCTGAGAGAGGATTTTAGC Deep Sequencing
EMX1.4_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCTTTGGGGGTGGAATTACTG Deep Sequencing
EMX1.5_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGGGCTCCCATCACATCAAC Deep Sequencing
EMX1.5_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TTGTCCCTCTGTCAATGGCG Deep Sequencing
EMX1.5_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GCTATGGCAGGATTTGTCAAGG Deep Sequencing
EMX1.5_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CCCACAAACATTCACACACTCA Deep Sequencing
EMX1.5_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CCTACCCACCTCCTACTGCT Deep Sequencing
EMX1.5_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TGTATGCTAGGCACAGAGGC Deep Sequencing
FANCF.1_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CTCCAGAGCCGTGCGAATG Deep Sequencing
FANCF.1_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    AATCAGTACGCAGAGAGTCGC Deep Sequencing
FANCF.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GACACGGGACACCCAGG Deep Sequencing
FANCF.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CAGAAATCTCCCACGAGTCTCC Deep Sequencing
FANCF.1_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TGGGGTTTCATGCTCTCTTCA Deep Sequencing
FANCF.1_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CCTTTCTTGTCTCTGGCGCT Deep Sequencing
FANCF.1_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TCATAGAGCTTCACCCTGTCCA Deep Sequencing
FANCF.1_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCTGGTGCTTTGAGATGCAAAA Deep Sequencing
POLQ.1_OnTar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GCTGCCAAGGAAAACAGATG Deep Sequencing
POLQ.1_OnTar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CCAAGCAAAGTACTGAAATGCTA Deep Sequencing
POLQ.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    CCCCAAGTGTAGTGCTGAAG Deep Sequencing
POLQ.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TCCAACCAGCAGTACATGAAG Deep Sequencing
IL12A-AS.1_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TTTCCCTGAAAAGGTGTTGC Deep Sequencing
IL12A-AS.1_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TCCTTCCATCTGGGTTTCTG Deep Sequencing
IL12A-AS.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AGGGTGGAACAGAGGAGGAA Deep Sequencing
IL12A-AS.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CAAGACCAGGAAGGAGGCTG Deep Sequencing
RPL32P3.1_OnTar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TCCTCACCACCTGTTTGTTG Deep Sequencing
RPL32P3.1_OnTar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    AGGGAAAACAACCTGGACAC Deep Sequencing
RPL32P3.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GGTGCCCACATTTCTCTCTC Deep Sequencing
RPL32P3.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GCGTCACATTAGTGCCATTG Deep Sequencing
RPL32P3.1_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TGGTCTGGAAGTCCAAGAGG Deep Sequencing
RPL32P3.1_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CCGGTCCCACTTCTCTCTCT Deep Sequencing
RPL32P3.1_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GGGGTGGGTGGAAGTTAGTT Deep Sequencing
RPL32P3.1_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TCTTTTGACTCCGCCTGACT Deep Sequencing
RPL32P3.1_OT4_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TTCGCAGCCTCCAATCTAGT Deep Sequencing
RPL32P3.1_OT4_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    CAAGCTTCTTTCAGCCATCC Deep Sequencing
DNMT1.1_Ontar_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    AACCCTCTGGGGACCGTTTG Deep Sequencing
DNMT1.1_Ontar_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    AGTCACTCTGGGGAACACGC Deep Sequencing
DNMT1.1_OT1_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TGTCTGCTGGAAGCTCCTATTC Deep Sequencing
DNMT1.1_OT1_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    GAAAGTTTAGCATGGAGGAGAGG Deep Sequencing
DNMT1.1_OT2_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    GCTCTTCCCCTCAACCACTA Deep Sequencing
DNMT1.1_OT2_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    TGTGGATGCTCAGGAAGTTTC Deep Sequencing
DNMT1.1_OT3_FWD TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG    TATGAGTGGGGTAGGGGAGG Deep Sequencing
DNMT1.1_OT3_REV GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG    ATGCATGCCTAGGAAGTTGC Deep Sequencing
sgRNA RT Primer GGTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG NNNNNNNNNN GCACCGACTCGGTGCCACTT 5' RACE, RNA-Seq N's indicate a random unique molecular identifier
Template Switch Oligo AAGCAGTGGTATCAACGCAGAGTGAATrGrGrG 5' RACE, RNA-Seq
Lib_Recovery_FWD AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGT*G*A 5' RACE, RNA-Seq 3' end of primer was chemically modified for stability
Lib_Recovery_REV CAAGCAGAAGACGGCATACGAGAT NNNNNN GTCTCGTGGGCTCGG 5' RACE, RNA-Seq N's indicate a specific barcode sequence
Custom_R1_Primer GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTGA 5' RACE, RNA-Seq
